

Curriculum Vitae

PART I: General Information

**DATE PREPARED:** January, 2022

**Name:** David M. Nathan, M.D.

**DEMOGRAPHIC INFORMATION:**

<b>Office Addresses:</b>	Diabetes Unit	MGH Diabetes Center
	Massachusetts General Hospital	50 Staniford Street
	Bulfinch 408	Suite 340
	Boston, MA 02114	Boston, MA 02114
	Tel: 617-726-2875	617-724-0775
	Fax: 617-726-6781	617-724-8534
	Page: 617-726-2066	

**Email:** [dnathan@mgh.harvard.edu](mailto:dnathan@mgh.harvard.edu)

**Home Address:** 80 Temple Street  
West Newton, MA 02465  
Tel: 617-332-4935

**Place of Birth:** New York, NY

Education:

1971 B.A. Amherst College, Amherst, MA

1975 M.D. Mt. Sinai School of Medicine, New York, NY

Postdoctoral Training:

1975-1976 Intern in Medicine, Peter Bent Brigham Hospital

1976-1977 Assistant Resident in Medicine, Peter Bent Brigham

1977-1978 Senior Resident in Medicine, Peter Bent Brigham Hospital

1977-1978 Chief Resident in Medicine, West Roxbury V.A. Hospital

Licensure and Certification:

1975 Massachusetts License Registration No. 42740

1976 Diplomate, National Board of Medical Examiners

1977 Diplomate, American Board of Internal Medicine

1981 Diplomate, Endocrinology and Metabolism, American Board  
of Internal Medicine

Academic Appointments:

1975-1978 Clinical Fellow in Medicine, Harvard Medical School

1978-1980 Research Fellow in Medicine, Harvard Medical School

1980-1982 Instructor in Medicine, Harvard Medical School

1982-1987 Assistant Professor of Medicine, Harvard Medical School

1987-1999 Associate Professor of Medicine, Harvard Medical School

1999- Professor of Medicine, Harvard Medical School

Hospital or Affiliated Institution Appointments:

1978-1979	Clinical Fellow in Medicine, Massachusetts General Hospital
1980-1981	Clinical Assistant in Medicine, Massachusetts General Hospital
1981-1984	Assistant in Medicine, Massachusetts General Hospital
1984-1987	Assistant Physician, Massachusetts General Hospital
1985-1986	Acting Chief, Diabetes Unit, Massachusetts General Hospital
1988-1996	Associate Physician, Massachusetts General Hospital
1996-	Physician, Massachusetts General Hospital
2011-2014	Physician, Department of Medicine, Brigham and Women's Hospital

Major Administrative Responsibilities:

1980-2016	Director, Diabetes Clinic, Massachusetts General Hospital
1983-	Director, Diabetes Center and Diabetes Research Center, Massachusetts General Hospital
1990-2008	Director, Mallinckrodt General Clinical Research Center
2008-	Director, MGH Clinical Research Center of the Harvard Catalyst (CTSC) Program
2008-2011	Institutional Representative for MGH, Harvard Catalyst (CTSC)
2008-	Primary Physician, Pancreas and Pancreas/Kidney Transplantation Program, Massachusetts General Hospital
2011-2014	Primary Physician, Pancreas Transplantation Program, Brigham and Women's Hospital

Major Committee Assignments:

1986-1988	Hospital Safety Committee, Massachusetts General Hospital
1989-1990	Scientific Advisory Committee, GCRC, Massachusetts General Hospital
1993	Clinical Research Task Force. Chairman, Clinical Physiology Research Subcommittee; Co-chairman, Clinical Trials Subcommittee
1995-2000	Committee on Research, Massachusetts General Hospital
1995-	Clinical Research Council, Massachusetts General Hospital
2000-2008	Executive Committee and Founding Member, Scholars in Clinical Science Program
2000-2004	Executive Committee on Research, Massachusetts General Hospital
2004-2010	Diabetes Council, Partners Health
2006-2008	Executive Committee, CTSA, Harvard Medical School Chairman, "Incubator, Research Support" Subcommittee
2008-	Executive Committee on Research, Massachusetts General Hospital

Professional Societies:

1971	Sigma Xi, Amherst College Chapter
1974	Alpha Omega Alpha, Mt. Sinai School of Medicine
1975	Alpha Omega Alpha, President
1980-	American Diabetes Association
1981-1986	Board of Directors, American Diabetes Association, Massachusetts Affiliate
1983	National Diabetes Advisory Board, Insulin Delivery Workgroup
1984	Special Study Section, Diabetes, NIADDK
1985-1987	American Diabetes Association, National Committee on Professional Education
1992	Special Committee on Clinical Trials, NIDDK
1994	American Society of Clinical Investigation

1995-2001	Member, Subspecialty Board Diabetes, Endocrinology, and Metabolism, American Board of Internal Medicine
1996-1997	Professional Practices Committee, American Diabetes Association
1996	Member, Juvenile Diabetes Foundation Research Task Force
1996-present	Founding member, National Glycohemoglobin Standardization Program
1997	Co-chairman, Diabetes Therapy Subcommittee of NIH Special Task Force on Directions for Diabetes Care and Research
2001	Chair, American Diabetes Association Panel on Postprandial Glycemia
2002- 2005	Member, Expert Committee on the Diagnosis and Classification of Diabetes Mellitus, American Diabetes Association
2003-2004	Member, Institute of Medicine Committee on Crossing the Quality Chasm
2003-2009	Member, World Health Organization Prevention and Treatment of Diabetes Group
2005-2010	Chair, American Diabetes Association/European Association for the Study of Diabetes Committee on Treatment of Type 2 diabetes mellitus
2006	Chair, American Diabetes Association, Consensus Committee on IFG/IGT
2007	Chair, Planning for future NIDDK clinical trials. NIDDK, NIH
2008-	Chair, Expert Committee on the Diagnosis of Diabetes, American Diabetes Association, European Association for the Study of Diabetes, International Diabetes Federation, World Health Organization
2008	Co-chair, Individualizing therapy of type 2 diabetes, Endocrine Society-ADA program
2009	Chair, Clinical Research/Clinical Trials section, NIDDK 10 year strategic plan
2010	Co-Chair, Clinical Recommendations Panel on Closed Loop Systems, Juvenile Diabetes Research Foundation

#### Major Research Project Responsibilities

1981-1987	Co-principal Investigator – Cognitive and Sensory Function in the Aging Diabetic, National Institute on Aging, NIH
1982-1995	Principal Investigator at Massachusetts General Hospital for <u>Diabetes Control and Complications Trial</u> , a multicenter, NIH-supported 10-year study: Steering Committee (1982-1995) Planning Committee (1985-1995) Treatment Committee (1982-1985) Clinic Monitoring Group (1983-1985) Publications and Presentations Committee (1982-1995) Chair (1985-1995) Editor for DCCT Publications (1985-1995)
1988- 1998	Co-investigator, diabetes investigations for <u>Framingham Heart Study</u>
1990- 1996	Co-investigator of <u>PORT</u> study on “Variations in the Management and Outcome of Type II Diabetes”, AHCPR
1990- 1994	Co-investigator of <u>Nurses Health Study</u> . Channing Labs, Boston, MA
1994-	Principal Investigator, <u>Epidemiology of Diabetes, Interventions and Complications Trial</u> . NIDDK, NIH
1994-2015	Co-Chair, <u>Epidemiology of Diabetes, Interventions and Complications Trial</u> . Long-term Follow-up of DCCT, NIDDK
1994-2002	Chair, <u>Diabetes Prevention Program</u> . NIH Multicenter Trial

1996- Founding member, National Glycohemoglobin Standardization Group  
1999- Principal Investigator, Look:AHEAD clinical trial. NIDDK, NIH  
1999-2004 Director, Clinical Research Trials for JDF-Harvard Islet  
Transplantation Center  
2000-2002 Steering Committee, Prevention and Treatment of Type 2  
diabetes in children and adolescents. NIDDK, NIH  
2001-2012 Data Safety Monitoring Board, ACCORD Study. NHLBI, NIH  
2002- Scientific Advisory Committee, CRIC Study. NIDDK, NIH  
2002- Scientific Advisory Committee, AASK Study. NIDDK, NIH  
2002- Principal Investigator, TODAY Study. NIDDK, NIH  
2002- Chair, Diabetes Prevention Program Outcome Study. NIDDK, NIH  
2005 Chair, External Advisory Committee, STOPP-T2D Study. NIDDK,  
NIH  
2005 External Advisory Committee, BARI-2D study. NHLBI, NIH  
2005-10 Principal Investigator, International Study of Mean Blood Glucose and  
HbA1c, American Diabetes Association, IDF, and EASD  
2010-12 Member, Scientific Advisory Board, Carlos Slim Health Institute  
2010- Principal Investigator and Chair, Glycemia Reduction Approaches in  
Diabetes: A Comparative Effectiveness (GRADE) Study  
2015- Chair, Epidemiology of Diabetes Interventions and Complications  
Study, NIDDK, NIH  
2016- Diabetes Consultant, Executive Committee for Trial to Assess  
Chelation Therapy (TACT-2) Study, NHLBI, NIH  
2016- Member, Clinical Study Oversight Committee, National Institute of  
Dental and Craniofacial Research (NICDR), NIH

Peer Review:

Frequent reviewer for *Diabetes*, *Diabetes Care*, *Diabetologia*, *New  
England Journal of Medicine*, *Journal of the American Medical  
Association*, *Journal of Clinical Investigation*, *Journal of Clinical  
Endocrinology and Metabolism*, *Annals of Internal Medicine*, *Lancet*,  
*Medical Letter*

Editorial roles:

1982-1987 Associate Editor, *Clinical Diabetes*, Journal of American Diabetes  
Association  
1986-1987 Contributing Editor, Type I Diabetes Textbook, ADA  
1986- Chairman, Publications Committee and Editorial Board,  
Diabetes Control and Complications Trial  
1988-1991 Editorial Board, *Diabetes Care*  
1991-1999 Author of "Diabetes Mellitus" and "Hypoglycemia" chapters in  
Scientific American Medicine series  
1991-1995 Editorial Board, *Journal of Diabetes and its Complication*  
1993-1998 Associate Editor, Yearbook of Endocrinology  
1995-1996 Editorial Board, *Diabetes*  
1996-2001 Associate Editor, *Diabetes*  
1997- Editor, *Epidemiology of Diabetes, Interventions and Complications  
(EDIC) Study*  
1997-2005 Editorial Board, *American Journal of Medicine*  
1997 Guest Editor, *Diabetes and the Heart*, *Lancet*, 1997 (suppl 1)  
2001-2003 Editorial Board, *Current Diabetes Reports*  
2002-2003 Editorial Board, *UpToDate*  
2003- Editor-in-Chief, *Diabetes and Endocrinology UpToDate*

2004- Editor, Harvard Medical School Publications, *Diabetes, A Plan for Living and Healthy Eating for Diabetics*

Awards and Honors:

1970 Sigma Xi  
1971 Magna Cum Laude graduate, English and Biology, Amherst College  
1971 Oscar E. Schotte Award for “Excellence in Scientific Research and Best Honors Thesis”  
1974 Alpha Omega Alpha  
1975 James Felt Memorial Prize for “Best All Around Performance During Four Years of Medical School”, Mt. Sinai School of Medicine  
1975 Mt. Sinai Journal of Medicine Prize  
1978 United States Veterans Administration Special Commendation for “Outstanding Performance as Chief Resident, West Roxbury VA Hospital”  
1981-83 Capps Scholar in Diabetes, Harvard University  
1987 Outstanding Service Award, American Diabetes Association  
1990-94 Senior Fellow, Walter Bradford Cannon Society, Harvard Medical School  
1994- American Society of Clinical Investigation  
1994 Charles Best Award, American Diabetes Association, as part of the DCCT Research Group  
1996-2004 Excellence in Teaching Award, Primary Care, MGH  
1997 Saul Horowitz, Jr. Memorial Award, for outstanding contributions in investigation and teaching, Mt. Sinai School of Medicine  
2001 American Association of Physicians  
2002 Outstanding Physician/Clinician Award, ADA  
2003 Modan Award for Outstanding Abstract in Epidemiology, ADA  
2004 Charles H. Best Award, Toronto Diabetes Association  
2010 Distinguished Scientist Award, NIDDK, NIH  
2014 Honorary Member, American Gynecological and Obstetrical Society  
2015 Inaugural Outstanding Achievement in Clinical Diabetes Research Award, American Diabetes Association  
2018 Abbas Kitabchi Distinguished Visiting Professorship, University of Tennessee Health Sciences College of Medicine  
2018 Outstanding Diabetes Investigator Award, Berrie Center, Columbia University  
2021 Inaugural F. John Service Memorial Lectureship, Mayo Clinic

**Part II: Bibliography**

***Original Articles (selected from more than 700 original articles):***

1. **Nathan DM.** The respiratory distress syndrome and glucocorticoid treatment: The case for enzyme induction. *Mt. Sinai J Med* 1975; 2:150-161.
2. **Nathan DM, Siegal AJ, Bunn HF.** Acute methemoglobinemia and hemolytic anemia with phenazopyridine. *Arch Int Med* 1977;137:1636-1638.
3. Thiemke WA, **Nathan DM.** Simultaneous nosocomial outbreaks caused by multiple resistant *Klebsiella pneumoniae* type 2 and 30. *J Clin Micro.* 1978;8:769-771.

4. **Nathan DM**, Daniels GH, Ridgway EC. Gastrinoma and pheochromocytoma: Is there mixed multiple endocrine adenoma syndrome? *Acta Endocrinologica* 1980; 93: 91-93.
5. **Nathan DM**, Axelrod L, Flier JS, Carr D. U-500 insulin in the treatment of antibody mediated insulin resistance. *Ann Intern Med* 1981; 94:653-656.
6. **Nathan DM**, Axelrod L, Proppe KH, Wald R, Hirsch HJ, Martin DB. Nesidioblastosis: A cause of insulin mediated hypoglycemia in an adult. *Diabetes Care* 1981; 4:383-388.
7. **Nathan DM**. Labile glycosylated hemoglobin contributes to hemoglobin A1 as measured by liquid chromatography or electrophoresis. *Clin Chem.* 1981; 27:1261-1263.
8. **Nathan DM**, Avezzano ES, Palmer JL. A rapid chemical means for removing labile glycohemoglobin. *Diabetes* 1981; 30:700-701.
9. **Nathan DM**. Successful treatment of extremely brittle, insulin-dependent diabetics with a new subcutaneous insulin pump regimen. *Diabetes Care* 1982; 5:105-110.
10. **Nathan DM**, Avezzano ES, Palmer JL. Rapid method to eliminate labile glycosylated hemoglobin from the assay for hemoglobin from the assay for hemoglobin A1. *Clin Chem.* 1982; 28:512-515.
11. **Nathan DM**, Lou PL, Avruch J. A crossover study of intensive conventional and insulin pump therapies in adult type I diabetes. *Ann Int Med.* 1982; 97:31-36.
12. **Nathan DM**, Francis TB, Palmer J. Effect of aspirin on glycosylated hemoglobin determinations. *Clin Chem.* 1983; 29:466-469.
13. **Nathan DM**. The importance of intensive supervision in determining the efficacy of insulin pump therapy. *Diabetes Care* 1983; 6:295-297.
14. Grinvalsky MA, **Nathan DM**. Diets for insulin pump and multiple daily injection therapy. *Diabetes Care* 1983; 6:241-244.
15. **Nathan DM**, Dunn BS, Francis TB. Two commercial methods evaluated for eliminating the labile fraction from the assay for glycated hemoglobin (glycohemoglobin). *Clin Chem.* 1984; 30:109-110.
16. **Nathan DM**, Singer DE, Hurxthal K, Goodson JD. The clinical information value of the glycosylated hemoglobin assay. *N Engl J Med* 1984; 310:341-346.
17. **Nathan DM**, Godine JE, Gauthier-Kelley C, Kawahara D, Grinvalsky M. Ice cream in the diet of insulin-dependent diabetic patients. *JAMA* 1984; 251:2825-2827.
18. **Nathan DM**, Raskin P. Convenient automated method for liquid chromatographic measurement of glycated hemoglobin. *Clin Chem* 1984;30:813-814.
19. Perlmutter LC, Hakami MK, Hodgson-Harrington C, Ginsberg J, Katz J, Singer DE, **Nathan DM**. Decreased cognitive function in aging non-insulin-dependent diabetics. *Am J Med.* 1984; 77:1043-1048.

20. Barbieri RL, Cooper DS, Daniels RH, **Nathan DM**, Klibanski A, Ridgway EC. Prolactin response to thyrotropin releasing hormone (TRH) in patients with hypothalamic-pituitary disease. *Fertility and Sterility* 1985; 43:66-73.
21. **Nathan DM**, Madnek SF, Delahanty L. Programming pre-exercise snacks to prevent post-exercise hypoglycemia in intensively treated insulin-dependent diabetes. *Ann Int Med.* 1985; 102:483-486.
22. Johnson RG, Godine JE, Hurxthal K, **Nathan DM**. The preparation of an acceptable placebo for NPH insulin. *Diabetes Care* 1985; 8:601-602.
23. Blackshear PJ, Shulman GI, Roussell AM, **Nathan DM**, et al. Metabolic response to three years of continuous, basal rate intravenous insulin infusion in type II diabetic patients. *J Clin Endo Metab.* 1985; 61:753-760.
24. Godine JE, Hurxthal K, **Nathan DM**. Bedside capillary glucose measurement by staff nurses in a general hospital. *Am J Med.* 1986; 80:803-806.
25. The Diabetes Control and Complications Trial (DCCT): Design and Methodologic Considerations - The DCCT Research Group. *Diabetes* 1986; 35:530-545.
26. **Nathan DM**. New methods for monitoring insulin-dependent diabetes: Clinical application and results. *J Kentucky Med Assoc.* 1986; 84:108-112.
27. **Nathan DM**, Singer DE, Godine JE, Harrington CH, Perlmutter LC. Retinopathy in older type II diabetics: Association with glucose control. *Diabetes* 1986; 35:797-801.
28. Trifiro M, **Nathan DM**. Purification of rat hepatic glucokinase. *Prep Biochem.* 1986; 1986; 16(2):155-173.
29. Goodson JD, Singer DE, Hurxthal K, **Nathan DM**. The limited clinical value of home urine testing in diabetic patients. *J Gen Int Med.* 1986; 1:243-247.
30. **Nathan DM**, Singer DE, Godine JE, Perlmutter LC. Non-insulin-dependent diabetes in the elderly: Complications and risk factors. *Am J Med.* 1986;81:837-842.
31. The Diabetes Control and Complications Trial (DCCT): Results of the feasibility study (phase II). The DCCT Research Group. *Diabetes* 1986;10:1-19.
32. Perlmutter LC, Tun PA, Sizer N, **Nathan DM**. Age and diabetes-related changes in verbal fluency. *Exp Aging Research* 1987; 13:9-14.
33. **Nathan DM**, Rosenbaum C, Protasowicki VD. Single void urine samples can be used to estimate quantitative microalbuminuria. *Diabetes Care* 1987; 10:414-418.
34. **Nathan DM**. The glycemic index: Meat and potatoes or just gravy? *Diabetes Care* 1987; 10:524-525.
35. Tun PA, Perlmutter LC, Russo P, **Nathan DM**. Memory self-assessment and performed in aged diabetics and non-diabetics. *Exp Aging Research* 1987; 13:151-157.

36. Goldstein DE, Soeldner S, Cleary PA, **Nathan DM**. Feasibility of centralized measurements of glycated hemoglobin in the Diabetes Control and Complications Trial (DCCT): A multicenter trial. *Clin Chem*.1987; 33:2267-71.
37. Geringer ES, Perlmutter LC, Stern TA, **Nathan DM**. Depression and diabetic neuropathy: A complex relationship. *J Ger Psych & Neuro*. 1988; 1:11-15.
38. Greene D, Brown MJ, Pfeifer M, Cleary PA, Gilbert PR, Neilsen VK, Rand DL, **Nathan DM**. Factors in the development of diabetic neuropathy: Baseline analysis of neuropathy in the feasibility phase of the Diabetes Control and Complications Trial (DCCT). *Diabetes* 1988; 37:476-481.
39. **Nathan DM**, Roussel A, Godine JE. Glyburide or insulin for metabolic control in non-insulin-dependent diabetes mellitus: A randomized double-blind study. *Ann Int Med*. 1988; 334-340.
40. Cosimi AB, Auchincloss H, Delmonico FL, Fang L, **Nathan DM**, Tolkoff-Rubin N, Rubin N, Russell PS. Combined pancreatic and renal transplantation in diabetics. *Arch Surg*. 1988; 123:621-625.
41. Perlmutter LC, **Nathan DM**, Goldfinger SH, Russo PA, Yates J, Larkin M. Triglyceride levels affect cognitive function in non-insulin-dependent diabetes mellitus. *J Diab Complications* 1988; 2:210-213.
42. **Nathan DM**. The modern management of insulin-dependent diabetes mellitus. *Med Clin NA*. 1988; 72:1365-1378.
43. Singer DE, Coley CM, Samet JM, **Nathan DM**. Screening for diabetes mellitus. *Ann Int Med* 1988; 109:639-649.
44. Singer DE, Samet JM, Coley CM, **Nathan DM**. Tests of glycemia in diabetes mellitus. *Ann Int Med* 1989; 110:125-137.
45. Singer DE, Moulton AW, **Nathan DM**. Diabetic myocardial infarction: Interaction with other pre-infarction risk factors. *Diabetes* 1989; 38:350-357.
46. Dunbar J, Cleary PA, Siebert C, Baker L, Brink S, **Nathan DM** for the DCCT Research Group. Implementation of a multicomponent process to obtain informed consent in the Diabetes Control and Complications Trial. *Controlled Clinical Trials* 1989; 10:83-96.
47. Blackshear PJ, Roussel AM, Cohen AM, **Nathan DM**. Basal rate intravenous insulin infusion compared to conventional insulin treatment in patients with type II diabetes. *Diabetes Care* 1989; 12:455-463.
48. Tun PA, **Nathan DM**, Perlmutter LC. Cognitive and affective disorders in elderly diabetics *Clin Geriatr Med* 1990;6:731-46.
49. **Nathan DM**, Fogel HA, Godine JE, Lou PL, D'Amico DJ, Regan CDJ, Topping TM. The role of the internist in evaluating diabetic retinopathy. *Diabetes Care* 1991; 14:26-33.

50. **Nathan DM**, Fogel HA, Norman D, Russell PS, Tolkoff-Rubin N, Delmonico FL, Auchincloss H, Camuso J, Cosimi AB. Long-term metabolic and quality of life results with pancreatic/renal transplantation in IDDM. *Transplantation* 1991; 52:85-91.
51. **Nathan DM**, Schreiber E, Fogel HA, Mojsov S, Habener JF. Preliminary studies of insulinotropic action of glucagon-like peptide- I (7-37) in diabetic and non-diabetic human subjects. *Diabetes Care* 1992; 15:270-276.
52. Singer DE, **Nathan DM**, Fogel HA, Schachat AP. Screening for diabetic retinopathy. *Ann Int Med.* 1992; 116:660-671.
53. Singer DE, Schachat AP, **Nathan DM**, Patz A, et al. Screening guidelines for diabetic retinopathy. *Ann Int Med* 1992; 116:684-685.
54. Singer DE, **Nathan DM**, Anderson KM, Wilson PWF, Evans JC. The association of hemoglobin A1C with prevalent cardiovascular disease in the original cohort of the Framingham Heart Study. *Diabetes* 1992; 41:202-208.
55. Dunn FL, Schrott HG, Oexmann MJ, Castle G, Cleary PA, Steffes MW, **Nathan DM** for the DCCT Research Group. Lipid and lipoprotein levels in patients with insulin-dependent diabetes mellitus: The Diabetes Control and Complications Trial (DCCT) experience. *Diabetes Care* 1992; 15:885-894.
56. Selam JL, Micossi P, Dunn FL, **Nathan DM**. Clinical trial of a programmable implantable pump for type I diabetes. *Diabetes Care* 1992; 15:877-885.
57. **Nathan DM**. The rationale for glucose control in diabetes mellitus. *Endocrinol. & Metab. North America* 1992; 21:221-235.
58. Manson JE, Rimm EB, Colditz GA, Willett WC, **Nathan DM**, Rosner B, Henekens CH, Speizer FE, Stampfer MJ. A prospective study of post-menopausal estrogen therapy and subsequent incidence of NIDDM. *Ann Epidemiol.* 1992; 2:665-673.
59. Manson JE, **Nathan DM**, Krolewski AS, Stampfer MJ, Willett WC. A prospective study of exercise and incidence of diabetes among U.S. male physicians. *JAMA* 1992; 268:63-67.
60. Lewandrowski K, Cheek R, **Nathan DM**, Godine JE, Hurxthal K, et al. Implementation of capillary blood glucose monitoring in a teaching hospital and determination of program requirements to maintain quality testing. *Am J Med* 1992; 93:419-426.
61. Cohen RM, **Nathan DM**, Clements RS. Hyperproinsulinemia in type II diabetes. *Diabetes Care* 1992; 15:723-24.
62. Molitch ME, Steffes MW, Cleary PA, **Nathan DM**. Baseline analyses of renal function in the Diabetes Control and Complications Trial. *Kidney International* 1993; 43:668-674.
63. **Nathan DM**. Long-term complications of diabetes mellitus. *N Engl J Med* 1993;328:676-685.
64. Fu Y, **Nathan DM**, Li F, Li X, Faustman DL. Defective MHC Class I expression on lymphoid cells in autoimmunity. *J Clin Invest* 1993; 91:2301-2307.

65. **Nathan DM**, Crofford OB, Genuth S, Lachin J, Rand L, Davis M, Siebert C, Cleary PA for the DCCT Research Group. The effect of intensive diabetes treatment on the development and progression of long-term complications in insulin-dependent diabetes mellitus: The Diabetes Control and Complications Trial. *N Engl J Med* 1993;329:978-986.
66. Habener JF, McManus K, **Nathan DM**. Insulinotropic actions of glucagon-like peptide 1-(7-37) in diabetic and non-diabetic subjects. *Digestion* 1993;54:376-78.
67. Greenfield S, Kaplan SH, Silliman R, Sullivan L, Manning W, D'Agostino R, Singer DE, **Nathan DM**. The uses of outcomes research for medical effectiveness, quality of care and reimbursement in type II diabetes. *Diabetes Care* 1994; 17(S1):32-39.
68. Lewandrowski E, Laposata M, Eschenbach K, Camosa C, **Nathan DM**, Godine JE, Hurxthal K, Goff J. Utilization and cost analysis of bedside capillary glucose testing in a large teaching hospital: Implications for the management of point-of-care testing. *Am J Med* 1994; 97:222-230.
69. **Nathan DM**. Prevention of long-term complications of non-insulin-dependent diabetes mellitus. *J Clin Invest Med* 1995; 18:332-339.
70. **Nathan DM**, Siebert C, Genuth S. DCCT: Design, outcome and implications. *IDF Bulletin* 1994; 39(S1):5-10.
71. Weir GC, **Nathan DM**, Singer DE. American Diabetes Association technical review on standards of care for diabetes. *Diabetes Care* 1994; 17:1514-1522.
72. **Nathan DM**. Inferences and implications: Do the DCCT results apply in NIDDM? *Diabetes Care* 1995; 18:251-257.
73. **Nathan DM**. Was it intensive therapy or glycemic control that worked in the DCCT? *Clinical Diabetes* 1995; 13:5-6.
74. Goldstein DE, Little RR, Lorenz RA, Malone JJ, **Nathan DM**, Peterson CM. Technical review on tests of metabolic status to monitor diabetes mellitus. *Diabetes Care* 1995; 18:896-909.
75. **Nathan DM**. The pathophysiology of diabetic complications: how much does the glucose hypothesis explain? *Ann Int Med* 1996; 124:86-90.
76. **Nathan DM**, McKittrick C, Larkin M, Schaffran R, Singer DE. Glycemic control in diabetes mellitus: have changes in therapy made a difference? *Am J Med* 1996; 100:157-63.
77. Meigs JB, **Nathan DM**, Cupples LA, Wilson PWF, Singer DE. Tracking of glycosylated hemoglobin in the original cohort of the Framingham Heart Study. *J Clin Epidemiol* 1996; 49:411-17.
78. **Nathan DM**, Dunn FL, Bruch J, McKittrick C, Larkin M, Haggan C, Lavin-Tompkins J, Norman D, Rogers D, Simon D. Post-prandial insulin profiles with implantable pump therapy may explain decreased frequency of severe hypoglycemia, compared with subcutaneous intensive regimens, in IDDM. *Am J Med* 1996; 100:412-17.

79. Chiasson JL, Josse RG, Leiter LA, Mihic M, **Nathan DM**, Palmason C, Cohen RM, Wolever TM. The effect of acarbose on insulin sensitivity in subjects with impaired glucose tolerance. *Diabetes Care* 1996; 19:1190-93.
80. Lachin, J, Genuth S, **Nathan DM** for the DCCT Research Group. The absence of a glycemic threshold for the development of long-term complications. *Diabetes* 1996; 45:1289-1298.
81. Dunn FL, **Nathan DM**, Scavini M, Selam J-L. Long-term therapy of IDDM with an implantable insulin pump. *Diabetes Care* 1997;20:59-63.
82. Meigs JB, Singer DE, Sullivan LS, Dukes KA, D'Agostino RB, **Nathan DM**, et.al. Metabolic control and prevalent cardiovascular disease in NIDDM: The NIDDM Patient Outcome Research Team. *Am J Med* 1997; 102:38-47.
83. Grinspoon S, Askari H, Landt M, **Nathan DM**, et al. Effects of fasting and glucose infusion on basal and overnight leptin concentrations in normal-weight women. *Am J Clin Nutr* 1997; 66:1352-6.
84. Meigs JB, D'Agostino RB, Wilson PWF, Cupples LA, **Nathan DM**, Singer DE. Risk variable clustering in the insulin resistance syndrome: the Framingham Offspring Study. *Diabetes* 1997; 46: 1594-1600.
85. **Nathan DM**, Meigs J, Singer DE. The epidemiology of cardiovascular disease in type 2 diabetes mellitus: how sweet it is ... or is it? *Lancet* 1997; 350 (suppl 1): 4-9.
86. Meigs JB, **Nathan DM**, Wilson PWF, Cupples LA, Singer DE. Metabolic risk factors worsen continuously across the spectrum of nondiabetic glucose tolerance. The Framingham Offspring Study. *Ann Int Med* 1998; 128:524-33.
87. **Nathan DM**. UKPDS- Some answers, more controversy. *Lancet* 1998; 352:832-33.
88. Genuth S, Eastman R, Kahn R, Klein R, Lachin J, Lebowitz H, **Nathan DM**, Vinicor F. Implications of the United Kingdom Diabetes Prospective Study. *Diabetes Care* 1999; 22(S1): S27-31.
89. Cohen RA, Hennekens CH, Christen WG, Krolewski A, **Nathan DM**, Petersen MJ, KaMotte F, Manson JE. Determinants of retinopathy progression in Type 1 diabetes mellitus. *Am J Med* 1999;107:45-51.
90. Cagliero E, Levina E, **Nathan DM**. Immediate feedback of HbA1c levels improves glycemic control in Type 1 and insulin-treated Type 2 diabetic patients. *Diabetes Care* 1999;22:1785-89.
91. **Nathan DM**. Treating Type 2 diabetes with respect. *Ann Int Med* 1999;130:440-441.
92. Meigs JB, Mittleman MA, **Nathan DM**, Tofler GH, Singer DE, Murphy-Sheehy PM, Lipinska I, D'Agostino RB, Wilson PWF. Hyperinsulinemia, hyperglycemia, and impaired hemostasis: the Framingham Offspring Study. *JAMA* 2000; 283: 221-28.
93. Lachin JM, Genuth S, Cleary P, Davis MD, **Nathan DM** for the EDIC Research Group. Retinopathy and nephropathy in patients with Type 1 diabetes four years after a trial of intensive therapy. *N Engl J Med* 2000; 342:381-9.

94. Meigs JB, **Nathan DM**, Ordovas JM, Schaefer EJ, Cupples LA, Singer DE, Wilson PWF. Apolipoprotein E isoform polymorphisms are not associated with insulin resistance. *Diabetes Care* 2000;23: 669-74.
95. Manson JE, Ajani UA, Liu S, **Nathan DM**, Hennekens CH. A prospective study of cigarette smoking and incidence of diabetes mellitus among U.S. male physicians. *Am J Med* 2000; 109:538-42.
96. Hu FB, Stampfer MJ, Solomon CG, Liu S, Willett WC, Speizer FE, **Nathan DM**, Manson JE. The impact of diabetes mellitus on mortality from all causes and coronary heart disease in women: 20 years of follow-up. *Arch Int Med* 2001; 161:1717-23.
97. Meigs JB, Jacques PF, Selhub J, Singer DE, **Nathan DM**, et al. Fasting plasma homocysteine levels in the insulin resistance syndrome. *Diabetes Care* 2001; 24:1403-1410.
98. Delahanty LM, Sonnenberg LM, Hayden D, **Nathan DM**. Clinical and cost outcomes of medical nutrition therapy for hypercholesterolemia: a controlled clinical trial. *JADA* 2001;101:1012-23.
99. Meigs JB, Haffner SM, **Nathan DM**, D'Agostino RB, Wilson PWF. Sample exchange to compare insulin measurements between the San Antonio Heart Study and Framingham Offspring Study. *J Clin Epidemiol* 2001; 54:1031-36.
100. Lopes de Faria JM, Katsumi O, Cagliero E, **Nathan DM**, Hirose T. Neurovisual abnormalities precede retinopathy in patients with long-term Type 1 diabetes. Graefe's *Arch Clin Exp Ophthalmol* 2001; 239: 643-48.
101. Knowler WC, Barrett-Connor E, Fowler S, Hamman R, Lachin J, Walker E, **Nathan DM** for the DPP Research Group. Reduction in incidence of Type 2 diabetes with life-style intervention or metformin. *N Engl J Med* 2002; 346:393-403.
102. Meigs JB, D'Agostino RB, **Nathan DM**, Rifal N, Wilson PWF. Longitudinal association of glycemia and microalbuminuria. *Diabetes Care* 2002; 25:977-83.
103. Grant RW, Cagliero E, Murphy-Sheehy P, Singer DE, **Nathan DM**, Meigs JB. Comparison of hyperglycemia, hypertension, and hypercholesterolemia management in patients with type 2 diabetes. *Am J Med* 2002;112: 603-609.
104. Genuth S, Lachin J, Cleary, P, **Nathan DM** for the DCCT/EDIC Research Group. Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus. *JAMA* 2002;287:2563-2569.
105. **Nathan DM**. The impact of clinical trials on the treatment of diabetes mellitus. *JCEM* 2002;87:1929-1935.
106. Barr GR, **Nathan DM**, Meigs JB, Singer DE. Tests of glycemia for the diagnosis of type 2 diabetes mellitus. *Ann Int Med* 2002;137:263-72.
107. Cagliero E, Apruzzese W, Perlmutter GS, **Nathan DM**. Musculoskeletal disorders of the hand and shoulder in patients with diabetes mellitus. *Am J Med* 2002; 112: 487-90.

108. Meigs JB, Larson MG, D'Agostino RB, Levy D, Clouse ME, **Nathan DM**, Wilson PWF, O'Donnell CJ. Coronary artery calcification in type 2 diabetes and insulin resistance. *Diabetes Care* 2002;25:1313-19.
109. Delahanty LM, Hayden D, Ammerman A, **Nathan DM**. Medical nutrition therapy for hypercholesterolemia positively affects patient satisfaction and quality of life outcomes. *Ann Behav Med* 2002;24:269-78.
110. Delahanty LM, Meigs JB, Hayden, **Nathan DM**. Psychological and behavioral correlates of baseline BMI in the Diabetes Prevention Program (DPP). *Diabetes Care* 2002; 25: 1992-1998.
111. **Nathan DM**. Initial management of glycemia in type 2 diabetes mellitus. *N Engl J Med* 2002; 347:1342-1349.
112. Meigs JB, **Nathan DM**, D'Agostino RB, Wilson PWF. Fasting and postchallenge glycemia and cardiovascular disease risk: the Framingham Offspring Study. *Diabetes Care* 2002; 25:1845-50.
113. Goldhaber-Fiebert J, Goldhaber-Fiebert S, Tristan ML, **Nathan DM**. Randomized controlled community-based nutrition and exercise intervention improves glycemia and cardiovascular risk factors in type 2 diabetes in rural Costa Rica. *Diabetes Care* 2003; 26: 24-29.
114. Meigs JB, Cagliero E, Dubey A, Murphy-Sheehy P, Gildesgame C, Chueh H, Barry MJ, Singer DE, **Nathan DM**. A controlled trial of web-based diabetes disease management: the MGH Diabetes Primary Care Improvement Project. *Diabetes Care* 2003;26:750-57.
115. Meigs JB, Muller DC, **Nathan DM**, Blake DR, Andres R. The natural history of progression from normal glucose tolerance to type 2 diabetes in the Baltimore Longitudinal Study of Aging. *Diabetes* 2003; 52:1475-84.
116. **Nathan DM**, Lachin J, Cleary P, Orchard T, Brillon DJ, Backlund J-Y, O'Leary DH, and Genuth S for the DCCT/EDIC Research Group. Intensive diabetes therapy and carotid intima-media thickness in type 1 diabetes mellitus. *N Engl J Med* 2003;348:2290-9.
117. Steffes MW, Chavers BM, Molitch ME, Cleary PA, Lachin JM, Genuth S and **Nathan DM** for the DCCT/EDIC Research Group. Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy. *JAMA* 2003; 290:2159-2167.
118. Meigs JB, Wilson PWF, **Nathan DM**, D'Agostino RB, Williams K, Haffner SM. Prevalence and characteristics of the metabolic syndrome in the San Antonio Heart and Framingham Offspring Studies. *Diabetes* 2003;52: 2160-7.
119. **Nathan DM**. Isolated pancreas transplantation for type 1 diabetes: a doctor's dilemma. *JAMA* 2003; 290: 2861-2863.
120. Blake DR, **Nathan DM**. Acute angle closure glaucoma following rapid correction of hyperglycemia. *Diabetes Care* 2003; 26:3197-8.

121. Huang ES, Gleason S, Gaudette R, Cagliero E, Murphy-Sheehy P, **Nathan DM**, Singer DE, Meigs JB. Health care resource utilization associated with a diabetes center and a general medicine clinic. *J Gen Int Med* 2004; 19:28-35.
122. **Nathan DM**, Herman WH. Screening for Diabetes: Can we afford not to screen? *Ann Int Med* 2004; 140: 756-58.
123. Grant RW, Cagliero E, Dubey AK, Gildesgame C, Chueh HC, Barry MJ, **Nathan DM**, Meigs JB. Clinical inertia in the management of Type 2 diabetes metabolic risk factors. *Diabetic Med* 2004 21:150-5.
124. Meigs JB, Williams K, Sullivan LM, Hunt KJ, Haffner SM, Stern MP, Villalpando CG, Perhanidis JS, **Nathan DM**, D'Agostino RB Jr, D'Agostino RB Sr, Wilson PWF. Using metabolic syndrome traits for efficient detection of impaired glucose tolerance. *Diabetes Care* 2004; 27: 1417-26.
125. Blake DR, Meigs JB, Muller DC, Najjar SS, Andres RA, **Nathan DM**. Impaired glucose tolerance, but not fasting glucose, is associated with increased levels of coronary heart risk factors: results from the Baltimore Longitudinal Study on Aging. *Diabetes* 2004; 53: 2095.
126. Grant RW, Cagliero E, Sullivan CM, Dubey AK, Estey GA, Weil EM, Gesmundo J, **Nathan DM**, et al. A controlled trial of population management. Diabetes mellitus: Putting Evidence into Practice (DM-PEP). *Diabetes Care* 2004; 27:2299-2305.
127. Miljanovic B, Glynn RJ, **Nathan DM**, Manson JE, Schaumberg DA. A prospective study of serum lipids and risk of diabetic macular edema in type 1 diabetes. *Diabetes* 2004; 53: 2883-2892.
128. Delahanty L, **Nathan DM**. Research navigating the course of clinical practice in diabetes. *J Am Diet Assoc* 2004; 104:1846-53.
129. Libby P, **Nathan DM**, Abraham K, Brunzell JD, Fradkin J, Haffner SM, Hsueh W, Rewers M, Roberts T, Savage P, Skarlatos S, Wassef M, Rabadan-Diehl C. Report of the National Heart, Lung and Blood Institute-National Institute of Diabetes and Digestive and Kidney Diseases Working Group on Cardiovascular Complications of Type 1 diabetes mellitus. *Circulation* 2005; 111:3489-93.
130. Wexler DJ, Grant RW, Meigs JB, **Nathan DM**, Cagliero E. Sex disparities in treatment of cardiac risk factors in patients with type 2 diabetes. *Diabetes Care* 2005; 28: 514-20.
131. Schaumberg DA, Glynn RJ, Jenkins AJ, Lyons TJ, Rifai N, Manson JE, Ridker PM, **Nathan DM**. Effect of intensive glycemic control on levels of markers of inflammation in Type 1 diabetes mellitus in the Diabetes Control and Complications Trial. *Circulation* 2005;111:2446-53.
132. **Nathan DM**, Cleary PA, Backlund J-YC, Genuth SM, Lachin JM, Orchard TJ, Raskin P, Zinman B. Intensive diabetes treatment and cardiovascular disease in type 1 diabetes mellitus. *N Engl J Med* 2005; 353:2643-2653.
133. Smith MR, Lee H, **Nathan DM**. Insulin sensitivity during combined androgen blockade for prostate cancer. *J Clin Endocrinol Metab* 2006; 91: 1305-8.

134. Meigs JB, O'Donnell CJ, Tofler GH, Benjamin EJ, Fox CS, Lipinska I, **Nathan DM**, Sullivan LM, D'Agostino RB, Wilson PW. Hemostatic markers of endothelial dysfunction and risk of incident type 2 diabetes in the Framingham Offspring Study. *Diabetes* 2006;55:530-7.
135. Delahanty LM, Conroy MB, **Nathan DM**. Psychological predictors of physical activity in the Diabetes Prevention Trial. *J Am Diet Assoc* 2006; 106:698-705.
136. Meigs JB, Wilson PW, Fox CS, Vasani RS, **Nathan DM**, Sullivan L, D'Agostino RB. Body mass index, metabolic syndrome and risk of type 2 diabetes or cardiovascular disease. *J Clin Endocrinol Metab* 2006; 91:2906-2912.
137. Florez JC, Jablonski KA, Bayley N, Pollin TI, deBakker PIW, Shuldiner AR, Knowler WC, **Nathan DM**, Altshuler D. Common genetic variants in the TCF7L2 gene influence progression to diabetes in the Diabetes Prevention Program. *N Engl J Med* 2006; 355:241-50.
138. Meigs JB, Wilson P, Fox C, Vasani R, **Nathan DM**, Sullivan L, D'Agostino Sr. RB. BMI, Metabolic Syndrome and Risk of Type 2 Diabetes or Cardiovascular Disease. *Clin Endocrinol Metab*. 2006;91:2906-12
139. **Nathan DM**, Buse JB, Davidson MB, Heine RJ, Holman RR, Sherwin R, Zinman B. Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy. *Diabetologia* 2006, 49:1711-1721. (Published simultaneously in *Diabetes Care* 2006; 29: 1963-72.
140. Cleary PA, Orchard TJ, Genuth S, Wong ND, Detrano R, Backlund J-Y, Zinman B, Jacobson B, Jacobson A, Sun W, Lachin JM, **Nathan DM**. The effect of intensive glycemic treatment on coronary artery calcification in type 1 diabetic participants of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) study. *Diabetes* 2006;55: 3556-3565.
141. Heine RJ, Diamant M, Mbanya JC, **Nathan DM**. Management of hyperglycemia in type 2 diabetes: the end of recurrent failure? *BMJ* 2006;333:1200-4.
142. **Nathan DM**. Thiazolidinediones for initial treatment of type 2 diabetes? *N Engl J Med* 2006;355: 2477-80.
143. **Nathan DM**. Finding New Treatments for Diabetes—How Many, How Fast . . . How Good? *N Engl J Med* 2007; 356: 437-440.
144. Florez JC, Jablonski KA, Kahn SE, Franks PW, Dabelea D, Hamman RF, Knowler WC, **Nathan DM**, Altshuler DA. Type 2 diabetes-associated missense polymorphisms KCNJ11 E23K and ABCC8 A1369S influence progression to diabetes and response to interventions in the Diabetes Prevention Program. *Diabetes* 2007; 56: 531-36.
145. Florez JC, Jablonski KA, Sun MA, Bayley N, Kahn SE, Shamon H, Hamman RF, Knowler WC, **Nathan DM**, Altshuler DA. Effects of the type 2 diabetes-associated PPARG P12A polymorphism on progression to diabetes and response to troglitazone. *J Clin Endocrinol Metab* 2007; 92:1502-09.

146. Wexler DJ, Meigs JB, Cagliero E, **Nathan DM**, Grant RW. Prevalence of hyper- and hypoglycemia among inpatients with diabetes. *Diabetes Care* 2007; 30:367-69.
147. **Nathan DM**. No time to inhale: Arguments against inhaled insulin in 2007. *Diabetes Care* 2007; 30: 442-43.
148. **Nathan DM**, Chew E, Christophi CA, Davis MD, Fowler S, Goldstein BJ, Hamman RF, Hubbard LD, Knowler WC, Molitch ME. The prevalence of retinopathy in impaired glucose tolerance and recent-onset diabetes in the Diabetes Prevention Program. *Diabet Med* 2007; 24: 137-144.
149. Lachin JM, Christophi CA, Edelstein SL, Ehrmann DA, Hamman RF, Kahn, SE, Knowler WC, **Nathan DM**. Factors associated with diabetes onset during metformin vs placebo therapy in the Diabetes Prevention Program. *Diabetes* 2007; 56:1153-9.
150. Lachin JM, Genuth S, **Nathan DM**, Rutledge BN. The hemoglobin glycation index is not an independent predictor of the risk of microvascular complications in the Diabetes Control and Complications Trial. *Diabetes* 2007; 56:1913-21.
151. **Nathan DM**, Berkwitz M. Trials that Matter: rosiglitazone, ramipril and the prevention of type 2 diabetes. *Ann Int Med* 2007; 146: 461-3.
152. Grant RW, Wexler DJ, Watson AJ, Lester WT, Cagliero E, Campbell EG, **Nathan DM**. How doctors choose medications to treat type 2 diabetes: a national survey of specialists and academic generalists. *Diabetes Care* 2007; 30:1448-53.
153. **Nathan DM**, Davidson MB, DeFronzo RA, Heine RJ, Henry RR, Pratley R, Zinman B. Impaired fasting glucose and impaired glucose tolerance: implications for care. *Diabetes Care* 2007; 30:753-9.
154. Wilson PWF, Meigs JB, Sullivan L, Fox CS, **Nathan DM**, D'Agostino RB. Prediction of incident diabetes mellitus in middle-aged adults. *Arch Int Med* 2007; 167: 1068-74.
155. **Nathan DM**. Rosiglitazone and cardiotoxicity-weighing the evidence. *N Engl J Med* 2007;357: 64-66.
156. **Nathan DM**, Turgeon H, Regan S. Relationship between glycated haemoglobin levels and mean glucose levels over time. *Diabetologia* 2007; 50:2239-2244.
157. Zee RY, Germer S, Thomas A, Raji A, Rhee B, Ridker PM, Lindpaintner K, Williams GH, **Nathan DM**, Martin M. C-reactive protein gene variation and type 2 diabetes mellitus: a case control study. *Atherosclerosis* 2007; PMID:17900590.
158. Lorenzi M, Fekete GT, Cagliero E, Pitler L, Schaumberg DA, Berisha F, **Nathan DM**, McMeel JW. Retinal haemodynamics in individuals with well-controlled type 1 diabetes. *Diabetologia* 2008; 51:361-4.
159. **Nathan DM**, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, Zinman B. Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy. Update on thiazolidinediones. *Diabetologia* 2008; 51: 8-11. (Published simultaneously in *Diabetes Care* 2008; 31: 173-5.

160. Pani L, **Nathan DM**, Grant RW. Clinical predictors of disease progression and medication initiation in untreated patients with type 2 diabetes and A1c < 7%. *Diabetes Care* 2008; 31: 386-90.
161. Lachin JM, Genuth S, **Nathan DM**, Zinman B, Rutledge BN for the DCCT/EDIC Research Group. The effect of glycemic exposure on the risk of microvascular complications in the Diabetes Control and Complications Trial—Revisited. *Diabetes* 2008; 57:995-1001.
162. Smith MR, Lee H, Fallon MA, **Nathan DM**. Adipocytokines, obesity and insulin resistance during combined androgen blockade for prostate cancer. *Urology* 2008; 71:318-22.
163. Hivert MF, Sullivan LM, Fox CS, **Nathan DM**, D'Agosino RB Sr, Wilson PW, Meigs JB. Association of adiponectin, resistin, and TNF alpha with insulin resistance. *J Clin Endo Metab* 2008; 93:3165-72.
164. Crandall JP, Knowler WC, Kahn SF, Marrero D, Florez JC, Bray GA, Haffner SM, Hoskin M, **Nathan DM**. The prevention of type 2 diabetes. *Nat Clin Pract Endocrinol Metab* 2008; 4: 382-93.
165. Delahanty LM, Nathan DM. Implications of the Diabetes Prevention Program and LookAHEAD clinical trials for lifestyle interventions. *J Am Diet Assoc.* 2008; 108:S66-72.
166. Ginde AA, Cagliero E, **Nathan DM**, Camargo CA Jr. Point-of-care glucose and hemoglobin A1c in emergency department patients without known diabetes: implications for opportunistic screening. *Acad Emerg Med* 2008; PMID: 18785943.
167. Pani L, Korenda L, Meigs JB, Driver C, Chamany S, Fox CS, Sullivan L, D'Agostino RB, **Nathan DM**. Effect of aging on A1c levels in persons without diabetes. Evidence from the Framingham Offspring Study and NHANES 2001-2004. *Diabetes Care* 2008; 31: 1991-6.
168. Ginde AA, Cagliero E, **Nathan DM**, Camargo CA Jr. Value of risk stratification to increase the predictive validity of HbA1c in screening for undiagnosed diabetes in the US population. *J Gen Intern Med* 2008; 23: 1346-53.
169. **Nathan DM**, Kuenen J, Borg R, Zheng H, Schoenfeld D, Heine RJ for the A1c Derived Average Glucose (ADAG) Study Group. Translating the A1c assay into estimated average glucose values. *Diabetes Care* 2008; 31: 1473-8.
170. Larkin ME, Capasso VA, Chen CL, Mahoney EK, Hazard B, Cagliero E, **Nathan DM**. Measuring psychological insulin resistance: barriers to insulin use. *Diabetes Educ.* 2008; 34: 511-17.
171. Wexler DJ, **Nathan DM**, Grant RW, Regan S, Van Leuvan AL, Cagliero E. Prevalence of elevated HbA1c among patients admitted to the hospital without a diagnosis of diabetes. *J Clin Endocrinol Metab* 2008;93:4238-44. PMID: 18697862.
172. Lin J, Glynn RJ, Rifai N, Manson JE, Ridker PM, **Nathan DM**, Schaumberg DA. Inflammation and progressive nephropathy in type 1 diabetes mellitus in the Diabetes Control and Complications Trial (DCCT). *Diabetes Care* 2008; 31:2338-43. PMID: 18796620.

173. **Nathan DM**, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, Zinman B. Medical management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy. *Diabetologia* 2009; 52: 17-30 PMID 18941734. (Published simultaneously in *Diabetes Care* 2009; 32: 192-203 PMID 18945920)
174. **Nathan DM**. How tight is right and how to get there. *Arch Int Med* 2008; 168:2064-6.
175. Pare G, Chasman DI, Parker AN, **Nathan DM**, Miletich JP, Zee RY, Ridker PM. Novel association of HKI with glycated hemoglobin in a non-diabetic population: a genome-wide evaluation of 14,618 participants in the Women's Genome Health Study. *PloS Genet* 2008; PMID: 19096518.
176. White NH, Sun W, Cleary PA, Danis RP, David MD, Hainsworth DP, Hubbard LD, Lachin JM, **Nathan DM**. Prolonged effect of intensive therapy on the risk of retinopathy complications in patients with type 1 diabetes mellitus: 10 years after the Diabetes Control and Complications Trial. *Arch Ophthalmol* 2008; 126: 1707-15. PMID: 19096518.
177. Delahanty LM, **Nathan DM**, Lachin JM, Hu FB, Cleary PA, Ziegler GK, Wylie-Rosett J, Wexler D for the DCCT/EDIC Research Group. Association of diet with glycated hemoglobin during intensive treatment of type 1 diabetes in the Diabetes Control and Complications Trial. *Am J Clin Nutr* 2009; 89:518-24.
178. **Nathan DM**, Zinman B, Cleary PA, Backlund J-Y, Genuth S, Miller R, Orchard TJ for DCCT/EDIC Research Group. Modern Day Clinical Course of Type 1 Diabetes Mellitus after 30-years Duration. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) and Pittsburgh Epidemiology of Diabetes Complications (EDC) Experience 1983-2005. *Arch Int Med* 2009; 169:1307-16.
179. **Nathan DM**. Progress in diabetes research- what's next. *JAMA* 2009; 301: 1599-1601.
180. Ai M, Otokozawa S, Schaefer EJ, Asztalos BF, Nakajima K, Shrader P, Kathiresan S, Meigs JB, Williams G, **Nathan DM**. Glycated albumin and direct low density lipoprotein cholesterol levels in type 2 diabetes mellitus. *Clin Chim Acta* 2009;406:71-4. PMID 19465013.
181. **Nathan DM**, Balkau B, Bonora E, Borch-Johnsen K, Buse JB, Colagiuri S, Davidson MB, et al. for the International Expert Committee on the Diagnosis of Diabetes. International Expert Committee Report on the Role of the A1C Assay in the Diagnosis of Diabetes. *Diabetes Care* 2009; 32: 1327-1334.
182. Grant RW, Hivert M, Pandiscio JC, Florez JC, **Nathan DM**, Meigs JB. The clinical application of genetic testing in type 2 diabetes: a patient and physician survey. *Diabetologia* 2009; 52:2299-2305. PMID 19727660
183. Kathiresan S, et al. Myocardial Infarction Genetics Consortium. Genome-wide association of early-onset myocardial infarction with single nucleotide polymorphisms and copy number variants. *Nat Genet* 2009;41:334-41.
184. Brownstein JS, Murphy SN, Goldfine AB, Grant RW, Sordo M, Gainer V, Colecchi JA, Dubey A, **Nathan DM**, Glaser JP, Kohane IS. Rapid identification of myocardial infarction

risk associated with diabetic medications using electronic medical records. *Diabetes Care*. 2010;33: 526-31 PMID: 20009093

185. **Nathan DM**. The role of glycemia management in the prevention of cardiovascular disease--starting over? *Ann Intern Med*. 2009 Dec 15;151(12):888-9. PMID: 20008764
186. Cole A, **Nathan DM**, Savaria-Porter E, Copeland P, Turchin A, Brunt M, Zusman R, Barrett JA, Wexler D, Case E, McMahan GT, Mort E. An algorithm for the care of type 2 diabetes. *Crit Pathw Cardiol*. 2009 Dec;8(4):156-65. PMID:19952550
187. Hivert MF, Sullivan LM, Shrader P, Fox CS, **Nathan DM**, D'Agostino RB Sr, Wilson PW, Benjamin EJ, Meigs JB. The association of tumor necrosis factor alpha receptor 2 and tumor necrosis factor alpha with insulin resistance and the influence of adipose tissue biomarkers in humans. *Metabolism*. 2010;59:540-6. PMID:19846171.
188. Knowler WC, Fowler SE, Hamman RF, Christophi CA, Hoffman HJ, Brenneman AT, Brown-Friday JO, Goldberg R, Venditti E, **Nathan DM** for the DPP Research Group. 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcome Study. *Lancet* 2009; 374:1677-86. PMID:19878986.
189. Cruz-Gonzales I, Chia S, Raffel OC, Sanchez-Ledesma M, Senatore F, Wackers FJ, **Nathan DM**, Jang IK. Hyperglycemia on admission predicts larger infarct size in patients undergoing percutaneous coronary artery intervention for acute ST-segment elevation myocardial infarction. *Diab Res Clin Pract* 2010; Epub ahead of print. PMID:20083319
190. Smith RJ, **Nathan DM**, Arslanian SA, Groop L, Rizza RA, Rotter JI. Individualizing therapies in type 2 diabetes mellitus based on patient characteristics: what we know and what we need to know. *J Clin Endocrinol Metabol*. 2010;95:1566-74. PMID:20194712.
191. **Nathan DM**. Navigating the choices for diabetes prevention. *N Engl J Med* 2010; Epub ahead of print. PMID:20228400.
192. El-Khatib FH, Russell SJ, **Nathan DM**, Sutherlin RG, Damiano E. A bi-hormonal closed-loop artificial pancreas for type 1 diabetes. *Sci Transl Med* 2010; Epub ahead of print. PMID: 204936998.
193. Borg R, Kuenen JC, Carstensen B, Zheng H, **Nathan DM**, Heine RJ, Nerup J, Borch-Johnsen K, Witte DR. Real-life glycemic profiles in non-diabetic individuals with low fasting glucose and normal HbA1c: the A1C-Derived Average Glucose (ADAG) study. *Diabetologia* 2010;53:1608-11. PMID: 20396998.
194. Larkin ME, Backlund J-Y, Cleary P, Bayless M, Schaefer B, Canady J, **Nathan DM**. Disparity in management of diabetes and coronary heart disease risk factors by sex in DCCT/EDIC. *Diabetic Medicine* 2010; 27: 451-8.
195. Borg R, Kuenen JC, Carstensen B, Zheng H, **Nathan DM**, Heine RJ, Nerup J, Borch-Johnsen K, Witte DR. Associations between features of glucose exposure and A1C. The A1c-Derived Average Glucose (ADAG) Study. *Diabetes* 2010; 59:1585-90.
196. **Nathan DM**, Steffes MW, Sun W, Rynders GP, Lachin JM. Determining the stability of stored samples retrospectively: the validation of glycated albumin. *Clin Chem*; 2010: PMID:21030684.

197. Russell SJ, El-Khatib FH, **Nathan DM**, Damiano ER. Efficacy determinants of subcutaneous microdose glucagon during closed-loop control. *J Diab Sci and Technol* 2010;4: 1288-304.
198. **Nathan DM**, Zheng H. Does the relationship between hemoglobin A1c and mean glucose levels differ by race? *Ann Intern Med* 2010;153:847-8.
199. Lopes-Virella MF, Hunt KJ, Baker NL, Lachin J, **Nathan DM**, Virella G. The Levels of Oxidized LDL and AGE- LDL in Circulating Immune Complexes are strongly associated with increased levels of Carotid Intima-Media Thickness and its progression in Type 1 *Diabetes*. 2010; PMID: 20980456.
200. **Nathan DM**. Time for clinically relevant comparative effectiveness studies in type 2 diabetes. *Ann Intern Med* 2011;153:131-2.
201. Borg R, Kuenen JC, Carstensen B, Zheng H, **Nathan DM**, Heine RJ, Nerup J, Borch-Johnsen K, Witte DR, ADAG Study Group. HbA1c and mean blood glucose show stronger associations with cardiovascular risk factors than do postprandial glycemia or glucose variability in persons with diabetes: the A1c-derived Average Glucose (ADAG) Study. *Diabetologia* 2011;54:69-72.
202. Smart-Halajko MC, Kelley-Hedgepeth A, Montefusco MC, Cooper JA, Kopin A, McCaffrey JM, Balasubramanyam A, Pownall HJ, **Nathan DM**, Peter I, Talmud PJ, Huggins GS; the Look AHEAD Study ANGPTL4 variants E40K and T266M are associated with lower fasting triglyceride levels in Non-Hispanic White Americans from the Look AHEAD Clinical Trial. *BMC Med Genet*. 2011 Jun 29;12(1):89
203. Kuenen JC, Borg R, Kuik DJ, Zheng H, Schoenfeld D, Diamant M, **Nathan DM**, Heine RJ; on behalf of the ADAG Study Group Does Glucose Variability Influence the Relationship Between Mean Plasma Glucose and HbA1c Levels in Type 1 and Type 2 Diabetic Patients? *Diabetes Care*. 2011;34:1843-1847.
204. Sacks DB, Arnold M, Bakris GL, Bruns DE, Horvath AR, Kirkman MS, Lernmark A, Metzger BE, **Nathan DM**. Executive summary: guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus. *Clin Chem*. 2011 Jun;57(6):793-8. Epub 2011 May 26. Published simultaneously in *Diabetes Care*
205. Eckel RH, Kahn SE, Ferrannini E, Goldfine AB, **Nathan DM**, Schwartz MW, Smith RJ, Smith SR. Obesity and type 2 diabetes: what can be unified and what needs to be individualized? *J Clin Endocrinol Metab*. 2011 Jun;96(6):1654-63. Published simultaneously in *Diabetes Care* 2011;34:1424-30.
206. de Boer IH, Rue TC, Cleary PA, Lachin JM, Molitch ME, Steffes MW, Sun W, Zinman B, Brunzell JD, White NH, Danis RP, Davis MD, Hainsworth D, Hubbard LD, **Nathan DM**; Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study Research Group. Long-term renal outcomes of patients with type 1 diabetes mellitus and microalbuminuria: an analysis of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications cohort. *Arch Intern Med*. 2011 Mar 14;171(5):412-20.
207. Hivert MF, Sullivan LM, Shrader P, Fox CS, **Nathan DM**, D'Agostino RB Sr, Wilson PW, Kowall B, Herder C, Meisinger C, Thorand B, Rathmann W, Meigs JB Insulin resistance influences the association of adiponectin levels with diabetes incidence in two population-

based cohorts: the Cooperative Health Research in the Region of Augsburg (KORA) S4/F4 study and the Framingham Offspring Study. *Diabetologia*. 2011 May;54(5):1019-24. Epub 2011 Feb 19.

208. Polak JF, Backlund JY, Cleary PA, Harrington AP, O'Leary DH, Lachin JM, **Nathan DM**; DCCT/EDIC Research Group. Progression of carotid artery intima-media thickness during 12 years in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) study. *Diabetes*. 2011; 60: 607-13.
209. Turkbey EB, Backlund JY, Genuth S, Jain A, Miao C, Cleary PA, Lachin JM, **Nathan DM**, van der Geest RJ, Soliman EZ, Liu CY, Lima JA, Bluemke DA, DCCT/EDIC Research Group. Myocardial structure, function and scar in patients with type 1 diabetes. *Circulation* 2011;124:1737-46.
210. Brancati FL, Evans M, Furberg CD, Geller N, Haffner S, Kahn SE, Kaufmann PG, Lewis CE, **Nathan DM**, Pitt B, Safford MM; Look AHEAD Study Group. Midcourse correction to a clinical trial when the event rate is underestimated: the Look AHEAD (Action for Health in Diabetes) Study. *Clin Trials*. 2012;9:113-24.
211. Pittas AG, Nelson J, Mitri J, Hillmann W, Garganta C, **Nathan DM**, Hu FB, Dawson-Hughes B; Diabetes Prevention Program Research Group. Plasma 25-hydroxyvitamin D and progression to diabetes in patients at risk for diabetes: an ancillary analysis in the Diabetes Prevention Program. *Diabetes Care*. 2012;35:565-73.
212. Wei NJ, Grant RW, **Nathan DM**, Wexler DJ. Effect of Hospital Admission on Glycemic Control One Year after Discharge. *Endocr Pract*. 2012; 9:1-22.
213. Zeitler P, Hirst K, Pyle L, Linder B, Copeland K, Arslanian S, Cutler L, **Nathan DM**, Tollefsen L, Wilfley D, Kaufman F for the TODAY Study. A clinical trial to maintain glycemic control in youth. *N Engl J Med* 2012; 366:2247-56.
214. **Nathan DM**. Understanding the long-term benefits and dangers of intensive therapy of diabetes. *Arch Int Med* 2012; 172:769-70.
215. Russell SJ, El-Khatib FH, **Nathan DM**, Magyar KL, Jiang J, Damiano ER. Blood Glucose Control in Type 1 Diabetes with a Bihormonal Bionic Endocrine Pancreas. *Diabetes Care*. 2012; Aug 24. [Epub ahead of print] PMID: 22923666
216. Faustman DL, Wang L, Okubo Y, Burger D, Ban L, Man G, Zheng H, Schoenfeld D, Pompei R, Avruch J, **Nathan DM**. Proof-of-Concept, Randomized, Controlled Clinical Trial of Bacillus-Calmette-Guerin for Treatment of Long-Term Type 1 Diabetes. *PLoS One*. 2012;7(8):e41756. Epub 2012 Aug 8. PMID: 22905105
217. **Nathan DM**. Diabetes: Long-acting insulin analogues-are benefits worth the cost? *Nat Rev Endocrinol*. 2012 Dec;8(12):699-700.
218. Purnell JQ, Hokanson JE, Cleary PA, **Nathan DM**, Lachin JM, Zinman B, Brunzell JD. The Effect of Excess Weight Gain with Intensive Diabetes Treatment on Cardiovascular Disease Risk Factors and Atherosclerosis in Type 1 Diabetes: Results from the Diabetes Control and Complications Trial / Epidemiology of Diabetes Interventions and Complications Study (DCCT/EDIC) Study. *Circulation*. 2012 Dec 4. [Epub ahead of print]

PMID: 23212717

219. Delahanty LM, Peyrot M, Shrader PJ, Williamson DA, Meigs JB, **Nathan DM**; for the DPP Research Group. Pretreatment, Psychological, and Behavioral Predictors of Weight Outcomes Among Lifestyle Intervention Participants in the Diabetes Prevention Program (DPP). *Diabetes Care*. 2013;36:34-40.
220. Wei NJ, Wexler D, **Nathan DM**, Grant RW. Intensification of diabetes medication and risk for 30-day readmission. *Diabet Med*. 2012 Nov 5. [Epub ahead of print] PMID: 23126686.
221. Wexler DJ, Beauharnais CC, Regan S, **Nathan DM**, Cagliero E, Larkin ME. Impact of inpatient diabetes management, education, and improved discharge transition on glycemic control 12 months after discharge. *Diabetes Res Clin Pract*. 2012;98(2):249-56.
222. Damiano ER, El-Khatib FH, Zheng H, **Nathan DM**, Russell SJ. A comparative effectiveness analysis of three continuous monitors. *Diabetes Care* 2013;36:251-9.
223. **Nathan DM**, Russell SJ. The future of care for type 1 diabetes. *CMAJ* 2013;185:285-6.
224. **Nathan DM**, Buse JB, Kahn SE, Krause-Steinrauf H, Larkin ME, Staten M, Wexler D, Lachin JM; GRADE Study Research Group. Rationale and Design of the Glycemia Reduction Approaches in Diabetes: a Comparative Effectiveness Study. *Diabetes Care* 2013;36:2254-61.
225. Look AHEAD Research Group, Wing RR, Bolin P, Brancati FL, Bray GA, Clark JM, Coday M, Crow RS, Curtis JM, Egan CM, Espeland MA, Evans M, Foreyt JP, Ghazarian S, Gregg EW, Harrison B, Hazuda HP, Hill JO, Horton ES, Hubbard VS, Jakicic JM, Jeffery RW, Johnson KC, Kahn SE, Kitabchi AE, Knowler WC, Lewis CE, Maschak-Carey BJ, Montez MG, Murillo A, **Nathan DM**, et al. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. *N Engl J Med* 2013;369:145-54.
226. Crane PK, Walker R, Hubbard RA, Li G, **Nathan DM**, Zheng H, Hasneuse S, Craft S, Miontine SJ, Kahn SE, McCormick W, McCurry SM, Bowen JD, Larson EB. Glucose levels and risk of dementia. *N Engl J Med* 2013;369:540-8.
227. **Nathan DM**, McGee P, Steffes MW, Lachin JM and the DCCT/EDIC Research Group. Relationship of glycated albumin to blood glucose and glycated hemoglobin (HbA1c) values and to retinopathy, nephropathy and cardiovascular outcomes in the DCCT/EDIC study. *Diabetes* 2013; PMID: 23990364.
228. **Nathan DM**, Bayless M, Cleary P, Genuth S, Gubitosi-Klug R, Lachin JM, Lorenzi G, Zinman B; DCCT/EDIC Research Group. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study at 30 years: advances and contributions. *Diabetes*. 2013;62:3976-86. PMID: 24264395
229. Kim C, Cleary PA, Cowie C, Braffett BH, Dunn RL, Larkin ME, Gatcomb P, Wessells H, **Nathan DM**, Sarma AV; for the DCCT/EDIC Research Group. Effect of glycemic treatment and microvascular complications on menopause in women with type 1 diabetes in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) cohort. *Diabetes Care*. 2013 Oct 29. [Epub ahead of print] PMID: 24170751

230. Anderson EJ, Sylvia LG, Lynch M, Sonnenberg L, Lee H, **Nathan DM**. Comparison of energy assessment methods in overweight individuals. *J Acad Nutr Diet*. 2013 :S2212-2672. PMID: 24051107
231. Lachin JM, Orchard TJ, **Nathan DM**; DCCT/EDIC Research Group. Update on cardiovascular outcomes at 30 years of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study. *Diabetes Care*. 2014;37:39-43. PMID: 24356596
232. **Nathan DM**; DCCT/EDIC Research Group. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study at 30 years: overview. *Diabetes Care*. 2014; 37:9-16. PMID: 24356592
233. Rutter MK, Sullivan LM, Fox CS, Wilson PW, **Nathan DM**, Vasani RS, D'Agostino RB Sr, Meigs JB. Baseline levels, and changes over time in body mass index and fasting insulin, and their relationship to change in metabolic trait clustering. *Metab Syndr Relat Disord*. 2014;12:372-80. PMID: 25007010
234. Lo C, Lui M, Ranasinha S, Teele HJ, Kerr PG, Polkinghouse K, **Nathan DM**, et al. Defining the relationship between average glucose and HbA1c in patients with type 2 diabetes and chronic kidney disease. *Diab Res Clin Pract* 2014; 104:84-95.
235. Russell SJ, El-Khatib FH, Sinha M, Magyar KL, McKeon K, Goergen LG, Balliro C, Hillard MA, **Nathan DM**, Damiano ER. Outpatient glycemic control with a bionic pancreas in type 1 diabetes. *N Engl J Med* 2014;371:313-25. PMID: 24931572
236. Damiano ER, McKeon K, El-Khatib FH, Zheng H, **Nathan DM**, Russell SJ. A comparative effectiveness analysis of three continuous glucose monitors: the Navigator, G4 Platinum and Enlite. *J Diabetes Sci Technol*. 2014;8:699-708. PMID: 24876423.
237. Rutter MK, Sullivan LM, Fox CS, Wilson PW, **Nathan DM**, Vasani RS, D'Agostino RB Sr, Meigs JB. Baseline and changes over time in body mass index and fasting insulin and their relationships to change in metabolic trait clustering. *Metab Syndr Relat Disord*. 2014;12: 372-80. PMID: 25007010
238. Wei NJ, Zheng H, **Nathan DM**. Empirically Establishing Blood Glucose Targets to Achieve HbA1c Goals. *Diabetes Care* 2014; 37: 1048-51.
239. Pownall HJ, Bray GA, Wagenknecht LE, Walkup MP, Heshka S, Hubbard VS, Hill J, Kahn SE, **Nathan DM**, Schwartz AV, Johnson KC; Look AHEAD Research Group. Changes in body composition over 8 years in a randomized trial of a lifestyle intervention: The look AHEAD study. *Obesity* 2015;23:565-72.
240. Wei NJ, **Nathan DM**, Wexler DJ. Glycemic control after hospital discharge in insulin-treated type 2 diabetes: a randomized pilot trial of daily remote glucose monitoring. *Endocr Pract*. 2015;21:115-21. PMID: 25148814.
241. Orchard TJ, **Nathan DM**, Zinman B, Cleary P, Brillon D, Backlund JY, Lachin JM for the DCCT/EDIC Research Group. Association between 7 years of intensive treatment of type 1 diabetes and long-term mortality. *JAMA* 2015;313:45-53. PMID: 25562265.

242. Aiello LP, Sun W, Das A, Gangaputra S, Kiss S, Klein R, Cleary PA, Lachin JM, **Nathan DM** and DCCT/EDIC Research Group. Intensive diabetes therapy and ocular surgery in type 1 diabetes. *N Engl J Med* 2015;372:1722-33. PMID: 25923552.
243. Bharucha AE, Batey-Schaefer B, Cleary PA, Murray JA, Cowie C, Lorenzi G, Driscoll M, Harth J, Larkin M, Christofi M, Bayless M, Wimmergren N, Herman W, Whitehouse F, Jones K, Kruger D, Martin C, Ziegler G, Zinmesiter AR, **Nathan DM**. Delayed gastric emptying is associated with early and long-term hyperglycemia in type 1 diabetes mellitus. *Gastroenterology* 2015;149:330-9. PMID: 25980755.
244. **Nathan DM**. Diabetes: Advances in diagnosis and treatment. *JAMA* 2015; 314:1052-62. PMID: 26348754.
245. Delahanty LM, Dalton KM, Porneala B, Chang Y, Goldman VM, Levy D, **Nathan DM**, Wexler DJ. Improving diabetes outcomes through lifestyle intervention- a randomized clinical trial. **Obesity** 2015; 23:1792-9. PMID: 26260043.
246. Ceglia L, Nelson J, Ware J, Alysandratos KD, Bray GA, Garganta C, **Nathan DM**, Hu FB, Dawson-Hughes B, Pittas AG; Diabetes Prevention Program Research Group. Association between body weight and composition and plasma 25-hydroxyvitamin D level in the Diabetes Prevention Program. *Eur J Nutr* 2015; epub. PMID: 26525562.
247. **Nathan DM**, Barrett-Connor E, Crandall JP, et al and the DPP Research Group. Long-term effects of lifestyle intervention or metformin on diabetes development and microvascular complications: the DPP Outcomes Study. *Lancet Diabetes Endocrinol* 2015;3:866-75.
248. **Nathan DM**, Bebu I, Braffett BH, Orchard TJ, et al. and the DCCT/EDIC Research Group. Risk factors for cardiovascular disease in type 1 diabetes. *Diabetes* 2016; PMID:26895792
249. Rubino F, **Nathan DM**, Eckel RH, Schauer PR, Alberti KG, et al. Metabolic surgery in the treatment algorithm for type 2 diabetes: a joint statement by international diabetes organizations. *Diabetes Care* 2016; 39:861-77. Simultaneously published in *Surg Obes Relat Dis.* 2016;12:1144-62 and *Obes Surgery* 2017; 27:2-21.
250. Adams TD, Arteburn DE, **Nathan DM**, Eckel RH. Clinical outcomes of metabolic surgery: microvascular and macrovascular complications. *Diabetes Care* 2016; 39:912-23.
251. Nathan DG, **Nathan DM**. Eulogy for the clinical research center. *J Clin Inv* 2016; 126:2388-91.
252. Ferris FL, **Nathan DM**. Preventing diabetic retinopathy progression. *Ophthalmology* 2016; 129:1840-2.
253. Malka R, **Nathan DM**, Higgins JM. Mechanistic modeling of hemoglobin glycation and red blood cell kinetics enables personalized diabetes monitoring. *Sci Transl Med* 2016; 8: 359. PMID: 27708063.
254. Lachin JM, Bebu I, Bergenstal RM, Pop-Busui R, Service FJ, Zinman B, **Nathan DM**, DCCT/EDIC Research Group. Association of glycemic variability in type 1 diabetes with

progression of microvascular outcomes in the Diabetes Control and Complications Trial. *Diabetes Care* 2017; 40:777-83. PMID: 28404658.

255. **Nathan DM**, Bebu I, Hainsworth D, Klein R, Tamborlane W, Lorenzi G, Gubitosi-Klug R, Lachin JM for the DCCT/EDIC Research Group. Frequency of evidence-based screening for retinopathy in type 1 diabetes *N Engl J Med* 2017; 376:1507-16. PMID: 28423305.
256. Bebu I, Braffett BH, Pop-Busui R, Orchard TJ, **Nathan DM**, Lachin JM, DCCT/EDIC Research Group. The relationship of blood glucose with cardiovascular disease is mediated over time by traditional risk factors in type 1 diabetes: the DCCT/EDIC study. *Diabetologia* 2017; 60: 2084-91. PMID: 28711972.
257. Aroda VR, Knowler WC, Crandall JP, Perreault L, Edelstein SL, Jeffries SL, Molitch ME, Pi-Sunyer X, Darwin C, Heckman-Stoddard BM, Temprosa M, Kahn SE, **Nathan DM**; Diabetes Prevention Program Research Group. Metformin for diabetes prevention: insights from the Diabetes Prevention Program/Diabetes Prevention Program Outcomes Study. *Diabetologia* 2017;60: 1601-11. PMID: 28770322.
258. Zekavat SM, Butkovich S, Young GJ, **Nathan DM**, Petrasek D. A computational model of 1,5-AG dynamics during pregnancy. *Physiol Rep* 2017;5[epub Aug 5]. PMID: 28821595
259. Majithia AR, Wiltschko AB, Zheng H, Walford GA, **Nathan DM**. Rate of change of premeal glucose measured by continuous glucose monitoring predicts postmeal glycemic excursions in patients with type 1 diabetes: implications for therapy. *J Diab Sci Technol* 2017;12: 76-82. PMID:28868899
260. **Nathan DM**. Adjunctive treatments for type 1 diabetes. *N Engl J Med* 2017;377:2390. PMID: 28899219
261. Arnold SE, Arvanitakis Z, Macauley-Rambach SL, Koenig AM, Wang HY, Ahima RS, Craft S, Gandy S, Buettner C, Stoekel LE, Holtzman DM, **Nathan DM**. Brain insulin resistance in type 2 diabetes and Alzheimer disease: concepts and conundrums. *Nat Rev Neurol* 2018;14: 168-81. PMID:29377010
262. Fan W, Zheng H, Wei N, **Nathan DM**. Estimating HbA1c from timed self-monitored blood glucose values. *Diabetes Res Clin Pract* 2018;141: 56-61. PMID: 296736846
263. Draznin B, **Nathan DM**, Korytkowski MT, McDonnell ME, Golden SH, Schutta MH, Cefalu WT. Guidelines versus guidelines: what's best for the patient? *Ann Int Med* 2018; 169:186-7. PMID: 30557433.
264. **Nathan DM**. Diagnosing diabetes mellitus- best practices still unclear. *Nat Rev Endocrinol* 2018;14:572-3. PMID: 30054564.
265. Pilla SJ, Balasubramanyam A, Knowler WC, Lazo M, **Nathan DM**, et al. Islet autoantibody positivity in overweight and obese adults with type 2 diabetes. *Autoimmunity* 2018;51:408-16.
266. Moreno RC, Navas-Acien A, Escolar E, **Nathan DM**, Newman J, Schmedtje JF, Diaz D, Lamas GA, Fonseca V. Potential role of metal chelation to prevent the cardiovascular complications of diabetes. *J Clin Endocrinol Metab.* 2019; epub ahead of print. PMID:

30869793.

267. **Nathan DM**; Diabetes Prevention Program Research Group. Long-term effects of metformin on diabetes prevention: identification of subgroups that benefitted most in the Diabetes Prevention Program and Diabetes Prevention Program Outcome Study. *Diabetes Care* 2019; 42: 601-9. PMID: 30877090.
268. Klonoff DC, Aron D, Cohn RM, Home P, John WG, Little RR, **Nathan DM**, Sacks DB. The need for accuracy in hemoglobin A1c proficiency testing: why the proposed CLIA rule of 2019 is a step backward. *J Diabetes Sci Technol* 2019;13:424-7. PMID: 30897963.
269. **Nathan DM**, Griffin A, Perez FM, Basque E, Do L, Steiner B. Accuracy of a point-of-care hemoglobin A1c assay. *J Diabetes Sci Technol* 2019; epub ahead of print. PMID: 30943787.
270. **Nathan DM**, Bennett PH, Crandall JP, Edelstein SL, Goldberg RB, Kahn SE, Knowler WC, Mather KJ, Mudalar S, Orchard TJ, Tempresa M, White NH; and the DPP Research Group. Does diabetes prevention translate into reduced long-term vascular complications of diabetes? *Diabetologia* 2019;62: 1319-28. PMID:31270584.
271. Larkin M, **Nathan DM**, Bebu I, Krause-Steinrauf H, Herman WH, Higgins JM, Titkin M, Cohen RM, Lund C, Bergenstal RM, Johnson M, Arends V; GRADE Research Group. Rationale and design for a GRADE substudy of Continuous Glucose Monitoring. *Diab Technol Ther* 2019; 21:682-690. PMID: 31393175.
272. Grashow R, Weisskopf MG, Miller KK, **Nathan DM**, Zafonte R, Speizer FE, Courtney TK, Baggish A, Taylor HA, Pascuale-Leone A, Nadler LM, Roberts AL. Association of concussion symptoms with testosterone levels and erectile dysfunction in former professional US-style football players. *JAMA Neurol* 2019 [epub ahead of print Aug 26]. PMID:31449296.
273. Smetana GW, **Nathan DM**, Dugdale DC, Burns RB. To what target A1c level would you treat this patient with type 2 diabetes?: Grand Rounds discussion from Beth Israel Deaconess Medical Center. *Ann Int Med* 2019; 171:505-13. PMID: 31569249.
274. Edelson PK, James KE, Leong A, Arenas J, Cayford M, Callahan MJ, Bernstein SN, Tangren JS, Hivert MF, Higgins JM, **Nathan DM**, Powe CE. Longitudinal changes in the relationship between hemoglobin A1c and glucose tolerance across pregnancy and postpartum. *J Clin Endocrinol Metab* 2020; 105:e99-107. PMID: 32010954.
275. Bebu I, Braffett BH, Orchard TJ, Lorenzi GM, **Nathan DM**, Herman WH, Lachin JM. Moderation of the effect of glycemia on the risk of cardiovascular disease in type 1 diabetes: the DCCT/EDIC study. *Diabetes Res Clin Pract* 2020; Online ahead of print. PMID: 33310124.
276. Zhang P, Atkinson KM, Bray G, Chen H, Clark JM, Coday M, Dutton GR, Egan C, Espeland MA, Evans M, Foreyt JP, Greenway FL, Gregg EW, Hazuda HP, Hill JO, Horton ES, Hubbard VS, Huckfeldt PJ, Jackson SD, Jakicic JM, Jeffery RW, Johnson KC, Kahn SE, Killean T, Knowler WC, Korytkowski M, Lewis CE, Maruthur NM, Michaels S, Montez MG, **Nathan DM**, Patricio J, Peters A, Pi-Sunyer X, Pownall H, Redmon B,

Rushing JT, Steinburg H, Wadden TA, Wing RR, Wyatt H, Yanovski SZ; Look AHEAD Research Group. Within-trial cost effectiveness of a structured lifestyle intervention in adults with overweight/obesity and type 2 diabetes: results from the Action for Health in Diabetes (LOOK AHEAD). *Diabetes Care* 2020. Online ahead of print. PMID: 33168654.

277. Lachin JM, **Nathan DM**, Zinman B, Bebu I. Comment on Miller and Orchard: Understanding metabolic memory: A tale of two studies. *Diabetes Care* 2020; 69: e7-e8. PMID: 32561623.
278. Munshi MN, Meneilly GS, Rodríguez-Mañas L, Close KL, Conlin PR, Cukierman-Yaffe T, Forbes A, Ganda OP, Kahn CR, Huang E, Laffel LM, Lee CG, Lee S, **Nathan DM**, Pandya N, Pratley R, Gabbay R, Sinclair AJ. Diabetes in Ageing: pathways for developing the evidence base for clinical guidance. *Lancet Diabetes Endocrinol.* 2020 Oct;8(10):855-867. PMID: 32946822
279. Look AHEAD Research Group, Yeh HC, Bantle JP, Cassidy-Begay M, Blackburn G, Bray GA, Byers T, Clark JM, Coday M, Egan C, Espeland MA, Foreyt JP, Garcia K, Goldman V, Gregg EW, Hazuda HP, Hesson L, Hill JO, Horton ES, Jakicic JM, Jeffery RW, Johnson KC, Kahn SE, Knowler WC, Korytkowski M, Kure A, Lewis CE, Mantzoros C, Meacham M, Montez MG, **Nathan DM**, Pajewski N, Patricio J, Peters A, Xavier Pi-Sunyer F, Pownall H, Ryan DH, Safford M, Sedjo RL, Steinburg H, Vitolins M, Wadden TA, Wagenknecht LE, Wing RR, Wolff AC, Wyatt H, Yanovski SZ. Intensive weight loss intervention and cancer risk in adults with type 2 diabetes: analysis of the Look AHEAD randomized clinical trial. *Obesity* 2020; 28:1678-86. PMID: 32841523.
280. Zhang P, Atkinson KM, Bray GA, Chen H, Clark JM, Coday M, Dutton GR, Egan C, Espeland MA, Evans M, Foreyt JP, Greenway FL, Gregg EW, Hazuda HP, Hill JO, Horton ES, Hubbard VS, Huckfeldt PJ, Jackson SD, Jakicic JM, Jeffery RW, Johnson KC, Kahn SE, Killean T, Knowler WC, Korytkowski M, Lewis CE, Maruthur NM, Michaels S, Montez MG, **Nathan DM**, Patricio J, Peters A, Pi-Sunyer X, Pownall H, Redmon B, Rushing JT, Steinburg H, Wadden TA, Wing RR, Wyatt H, Yanovski SZ; Look AHEAD Research Group. Within-trial cost-effectiveness of a structured lifestyle intervention in adults with overweight/obesity and type 2 diabetes: results from the Action for Health in Diabetes (Look AHEAD) study. *Diabetes Care* 2021;44: 67-74. PMID: 33168654.
281. Bebu I, Braffett BH, Orchard TJ, Lorenzi GM, **Nathan DM**, Herman WH, Lachin JM. Moderation of the effect of glycemia on the risk of cardiovascular disease in type 1 diabetes: the DCCT/EDIC study. *Diab Res Clin Pract* 2021;171: 108591. PMID: 33310124.
282. Izzy S, Tahir Z, Grashow R, Cote DJ, Jarrah AA, Dhand A, Taylor H, Whalen M, **Nathan DM**, Miller KK, Speizer F, Baggish A, Weisskopf MG, Zafonte R. Concussion and risk of chronic medical and behavioral health comorbidities. *J Neurotrauma* 2021;38: 1384-41. PMID: 33451255.
283. **Nathan DM**. Realising the long-term promise of insulin therapy: the DCCT/EDIC study. *Diabetologia* 2021; 64:1049-58. PMID: 33550441.

284. Bebu I, Keshavarzi S, Gao X, Braffett BH, Canty AJ, Herman WH, Orchard TJ, Dagogo-Jack S, **Nathan DM**, Lachin JM, Patterson AD; DCCT/EDIC Research Group. Genetic risk factors for CVD in type 1 diabetes. *Diabetes Care* 2021; 44: 1309-16. PMID: 33883194.
285. TODAY Study Group, Bjornstad P, Drews KL, Caprio S, Gugitosi-Klug R, **Nathan DM**, Tesfaldet B, Tryggestad J, White NH, Zeitler P. Long-term complications in youth-onset type 2 diabetes. *N Engl J Med* 2021; 285: 416-26. PMID: 34320286.
286. Lachin JM, Bebu I, **Nathan DM**, DCCT/EDIC Research Group. The beneficial effects of earlier versus later implementation of intensive therapy in type 1 diabetes. *Diabetes Care* 2021; Online ahead of print. PMID: 34380706.
287. Lachin JM, **Nathan DM**, DCCT/EDIC Research Group. Understanding metabolic memory: the prolonged influence of glycemia during the Diabetes Control and Complications Trial (DCCT) on future risks of complications during the study of the Epidemiology of Diabetes Interventions and Complications (EDIC). *Diabetes Care* 2021; Online ahead of print. PMID: 34548284.
288. O'Connell J, **Nathan DM**, O'Brien T, O'Keefe DT. Treatment of diabetes- To Pump or Not to Pump. *N Engl J Med* 2021; 385:2092-5.

**DCCT Research Group** Publications - selected from 75 original articles  
**(D.M. Nathan- Chairman, Editorial Board; Chairman, Publications  
and Presentations Committee and Corresponding Author for all manuscripts)**

289. **DCCT Research Group**. Are continuing studies of metabolic control and microvascular complications in IDDM justified?: the Diabetes Control and Complications Trial. *N Engl J Med* 1988; 318:246-50.
290. **DCCT Research Group**. Weight gain associated with intensive therapy in the Diabetes Control and Complications Trial. *Diabetes Care* 1988; 11:567-573.
291. **DCCT Research Group**. Epidemiology of severe hypoglycemia in the DCCT. *Am J Med* 1991; 90:450-459.
292. **DCCT Research Group**. A screening algorithm to identify clinically significant changes in neuropsychological function in the Diabetes Control and Complications Trial. *J Clin Exp Neuropsych* 1994; 16:303-316.
293. **DCCT Research Group**. The effect of intensive therapy on the development and progression of diabetic complications in adolescent subjects in the Diabetes Control and Complications Trial. *J of Pediatrics* 1994; 125:177-178.
294. **DCCT Research Group**. The effect of intensive diabetes treatment on the progression of diabetic retinopathy in insulin-dependent diabetes mellitus: The Diabetes Control and Complications Trial. *Arch Ophthalmol* 1995; 113:36-51.
295. **DCCT Research Group**. Implementation of conventional and intensive treatment in the Diabetes Control and Complications Trial. *Diabetes Care* 1995;18:361-376.
296. **DCCT Research Group**. The effect of intensive diabetes therapy on the development and progression of nephropathy in the Diabetes Control and Complications Trial. *Kid Int* 1995; 47:1703-1720.

297. **DCCT Research Group.** The effect of intensive diabetes therapy on the development and progression of neuropathy in the Diabetes Control and Complications Trial. *Ann Int Med* 1995; 122:561-568.
298. **DCCT Research Group.** Comparison of study populations in the Diabetes Control and Complications Trial and the Wisconsin Epidemiologic Study of Diabetic Retinopathy. *Arch Int Med* 1995; 155:745-754.
299. **DCCT Research Group.** The effect of intensive diabetes therapy on macrovascular disease and its risk factors in the Diabetes Control and Complications Trial. *Am J Cardiol* 1995; 75:894-903.
300. **DCCT Research Group.** Treatment-related adverse events in the Diabetes Control and Complications Trial. *Diabetes Care* 1995; 18:1415-1427.
301. **DCCT Research Group.** The association between glycemic exposure and long-term diabetic complications in the Diabetes Control and Complications Trial. *Diabetes* 1995; 44:968-983.
302. **DCCT Research Group.** Influence of intensive diabetes treatment on quality-of-life outcomes in the Diabetes Control and Complications Trial. *Diabetes Care* 1996;19:195-203.
303. **DCCT Research Group.** Treatment-related adverse events in the Diabetes Control and Complications Trial. *Diabetes Care* 1995; 18:1415-1427.
304. **DCCT Research Group.** The association between glycemic exposure and long-term diabetic complications in the Diabetes Control and Complications Trial. *Diabetes* 1995; 44:968-983.
305. **DCCT Research Group.** Influence of intensive diabetes treatment on quality-of-life outcomes in the Diabetes Control and Complications Trial. *Diabetes Care* 1996;19:195-203.
306. **DCCT Research Group.** Effects of intensive diabetes therapy on neuropsychological function in adults in the Diabetes Control and Complications Trial. *Ann Int Med.* 1996; 24:379-88.
307. **DCCT Research Group.** Pregnancy outcomes in the Diabetes Control and Complications Trial. *Am J Obstet Gynecol.* 1996;174:1343-53.
308. **DCCT Research Group.** Lifetime benefits of intensive therapy as practiced in the Diabetes Control and Complications Trial. *JAMA* 1996; 276:1409-15.
309. **DCCT Research Group.** Hypoglycemia in the Diabetes Control and Complications Trial. *Diabetes* 1997;46:271-286.
310. **DCCT Research Group.** Effect of intensive therapy on residual B-cell function in patients with type 1 diabetes in the Diabetes Control and Complications Trial. *Ann Int Med* 1998;128:517-23.
311. **DCCT Research Group.** Early worsening of diabetic retinopathy in the Diabetes Control and Complications Trial. *Arch Ophthalmol* 1998;116:874-886.
312. **DCCT Research Group.** The effect of intensive diabetes therapy and pregnancy on complications. *Diabetes Care* 2000; 23:1084-91.

313. **DCCT Research Group.** The effect of intensive diabetes therapy on body mass and body composition in the Diabetes Control and Complications Trial.
314. Hoedtke RD, Hampe CS, Bekris LM, Hobbs G, Bryner KD, Lernmark A, and the **DCCT Research Group.** *J of Neuroimmunol.* 2007;185:182-89.
- Diabetes Prevention Program (DPP) Publications (selected from ~200 publications).**  
(<https://dppos.bsc.gwu.edu/web/dppos/publications>)  
(*D.M. Nathan, Study Chairman*)
315. **Diabetes Prevention Program Research Group.** The Diabetes Prevention Program: Design and methods for a clinical trial in the prevention of type 2 diabetes mellitus. *Diabetes Care* 1999, 22:623-34.
316. **Diabetes Prevention Program Research Group.** Diabetes Prevention Program. Baseline characteristics of the randomized cohort. *Diabetes Care* 2000;23: 1619-29.
317. **Diabetes Prevention Program Research Group.** Hypertension, insulin, and proinsulin in participants with impaired glucose tolerance. *Hypertension* 2002; 40: 679-86.
318. **Diabetes Prevention Program Research Group.** The Diabetes Prevention Program: recruitment methods and results. *Cont Clin Trials* 2002;23: 1571-71.
319. **Diabetes Prevention Program Research Group.** The Diabetes Prevention Program (DPP): Description of the lifestyle intervention. *Diabetes Care* 2002;25:2165-71.
320. **Diabetes Prevention Program Research Group.** Costs associated with the primary prevention of type 2 diabetes mellitus in the Diabetes Prevention Program. *Diabetes Care* 2003; 26:36-47.
321. **Diabetes Prevention Program Research Group.** Effect of withdrawal from metformin on the development of diabetes in the Diabetes Prevention Program. *Diabetes Care* 2003;26:977-980.
322. **Diabetes Prevention Program Research Group.** Within-trial cost effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. *Diabetes Care* 2003; 26: 2518-2523.
323. Molitch ME, Fujimoto W, Hamman RF, Knowler WC for the **Diabetes Prevention Program Research Group.** The Diabetes Prevention Program and its global implications. *J Am Soc Nephrol* 2003; 14: S103-S107.
324. **DPP Research Group.** Achieving weight loss and activity goals among Diabetes Prevention Program lifestyle participants. *Obes Res* 2004;12: 1426-34.
325. **DPP Research Group.** Dietary intake in the Diabetes Prevention Program cohort: Baseline and 1- year post-randomization. *Ann Epidemiol* 2004; 14:763-72.
326. **DPP Research Group.** Strategies to identify adults at high risk for type 2 diabetes. *Diabetes Care* 2005; 28: 138-44.
327. Herman WH, Hoerger TJ, Brandle M, Hicks K, Sorensen S, Zhang P, Hamman RF, Ackermann RT, Engelgau MM, Ratner, **DPP Research Group.** The cost-effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance. *Ann Int Med* 2005;142:323-32.
328. **DPP Research Group.** Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors. *Diabetes Care* 2005; 28: 888-894.

329. **DPP Research Group.** Metformin and intensive lifestyle intervention on the prevention of the metabolic syndrome. *Ann Int Med* 2005; 142:611-619.
330. **DPP Research Group.** Depression symptoms and antidepressant medicine use in Diabetes Prevention Program participants. *Diabetes Care* 2005; 28:830-7.
331. **DPP Research Group.** The effect of intensive life style on inflammation and coagulation in Diabetes Prevention Program participants with impaired glucose tolerance. *Diabetes* 2005; 54: 1566-1572.
332. **DPP Research Group.** Prevention of type 2 diabetes with troglitazone. *Diabetes* 2005; 54: 1150-1156.
333. **DPP Research Group.** Role of insulin secretion and sensitivity in the evolution of type 2 diabetes in the Diabetes Prevention Program. *Diabetes* 2005;54: 2404-2414.
334. **DPP Research Group.** Lipid, lipoproteins, c-reactive protein, and hemostatic factors at baseline in the Diabetes Prevention Program. *Diabetes Care* 2005; 28:2472-247.
335. Brown JS, Wing R, Barrett-Connor E, Nyberg LM, Kusek JW, Orchard TJ, Na Y, Vittinghoff E, Kanaya AM, **DPP Research Group.** Lifestyle intervention is associated with lower prevalence of urinary incontinence in the Diabetes Prevention Program. *Diabetes Care* 2006; 29: 385-90.
336. Carthenon MR, Prineas RJ, Temprosa M, Zhang ZM, Uwaifo G, Molitch ME, **DPP Research Group.** The association among autonomic nervous system function, incident diabetes, and intervention arm in the Diabetes Prevention Program. *Diabetes Care* 2006; 29:914-19.
337. Kriska AM, Edelstein SL, Hamman RF, Otto A, Bray GA, Mayer-Davis EJ, Wing RR, Horton ES, Haffner SM, Regensteiner JG, **DPP Research Group.** Physical activity in individuals at risk for diabetes: Diabetes Prevention Program. *Med Sci Sports Exerc.* 2006; 38: 826-32.
338. **DPP Research Group.** The influence of age on the effects of lifestyle modification and metformin in prevention of diabetes. *J Gerontol* 2006; 61:1075-81.
339. Florez JC, Jablonski KA, McAteer J, Sandhu MS, Wareham NJ, Barroso I, Franks PW, Altshuler D, Knowler WC for the **Diabetes Prevention Program.** Testing of diabetes-associated WFS1 polymorphisms in the Diabetes Prevention Program. *Diabetologia.* 2007 Dec 4; 18.
340. **Diabetes Prevention Program Research Group.** Body size and shape changes and the risk of diabetes in the Diabetes Prevention Program(DPP). *Diabetes.*2007;56:1680-5.
341. Herman WH, Ma Y, Uwaifo G, Haffner S, Kahn SE, Horton ES, Lachin JM, Montez MG, Brenneman T, Barrett-Connor E for the **Diabetes Prevention Program Research Group.** Differences in A1C by race and ethnicity among patients with impaired glucose tolerance in the Diabetes Prevention Program. *Diabetes Care.* 2007; 30(10):2453-7.

342. Moore AF, Jablonski KA, McAteer JB, Saxena R, Pollin TI, Franks PW, Hanson RL, Shulkdiner AR, Knowler WC, Altshuler D, Florez JC, **Diabetes Prevention Program**. Extension of type 2 diabetes genome-wide association scan results in the Diabetes Prevention Program. *Diabetes* 2008;57: 2503-10.
343. **Diabetes Prevention Program Research Group**. Prevention of diabetes in women with a history of gestational diabetes: effects of metformin and lifestyle interventions. *J Clin Endocrinol Metab* 2008; 93:4774-9. PMID: 18826999.
344. **Diabetes Prevention Program Research Group**. 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. *Lancet* 2009; 374:1677-86.
345. Crandall JP, Polsky S, Howard AA, et al. and the **DPP Research Group**. Alcohol consumption and diabetes risk in the Diabetes Prevention Program. *Am J Clin Nutr* 2009;90:595-601.
346. Perrault L, Kahn SE, Christophi CA, et al. and the **DPP Research Group**. Regression from pre-diabetes to normal glucose regulation in the Diabetes Prevention Program. *Diabetes Care* 2009; 32:1583-88.
347. Franks PW, Jablonski KA, Delahanty LM, et al. and the **Diabetes Prevention Program Research Group**. Assessing gene-treatment interactions at the FTO and INSIG2 loci on obesity-related traits. *Diabetologia* 2008;51:2214-23.
348. Moore AF, Jablonski KA, Mason CC et al. for the **DPP Research Group**. The association of ENPP1 K121Q with diabetes incidence is abolished by lifestyle modification in the Diabetes Prevention Program. *J Clin Endo Metab* 2009;94:449-53.
349. Ma Y, Temprosa M, Fowler S, et al. for the **Diabetes Prevention Program Research Group**. Evaluating the accuracy of an aneroid sphygmomanometer in a clinical trial setting. *Am J Hypertens* 2009;22:263-6.
350. Goldberg RB, Temprosa M, Haffner S et al. for the **Diabetes Prevention Program Research Group**. Effect of progression from impaired glucose tolerance to diabetes on cardiovascular risk factors and its amelioration by lifestyle and metformin: the Diabetes Prevention Program. *Diabetes Care* 2009;32:726-32.
351. Florez H, Ma Y, Crandall JP, Perreault L, Marcovina SM, Bray GA, Saudek CD, Barrett-Connor E, Knowler WC; for the **Diabetes Prevention Program Research Group**. Parental Longevity and Diabetes Risk in the Diabetes **Prevention Program**. *J Gerontol A Biol Sci Med Sci*. 2011 Aug 17.
352. Majithia AR, Jablonski KA, McAteer JB, Mather KJ, Goldberg RB, Kahn SE, Florez JC; for the **DPP Research Group**. Association of the SLC30A8 missense polymorphism R325W with proinsulin levels at baseline and after lifestyle, metformin or troglitazone intervention in the Diabetes Prevention Program. *Diabetologia*. 2011 Jul 21.
353. Perreault L, Pan Q, Mather KJ, Watson KE, Hamman RF, Kahn SE for the **DPP Research Group**. Effect of regression from prediabetes to normal glucose regulation on long-term

reduction in diabetes risk: results of the Diabetes Prevention Program Outcome Study. *Lancet* 2012;379: 2243-51. PMID 22683134.

354. Pollin TI, Isakova T, Jablonski KA, de Bakker PI, Taylor A, McAteer J, Pan Q, Horton ES, Delahanty LM, Altshuler D, Shuldiner AR, Goldberg RB, Florez JC, Franks PW; **Diabetes Prevention Program Research Group**. Genetic Modulation of Lipid Profiles following Lifestyle Modification or Metformin Treatment: The Diabetes Prevention Program. *PLoS Genet*. 2012 Aug;8(8):e1002895. Epub 2012 Aug 30
355. Christophi CS, Resnick HE, Ratner RE, Temprosa M, Fowler S, Knowler WC, Shamon H, Barrett-Connor E, Kahn SE, **Diabetes Prevention Program Research Group**. *J Diabetes Complications* 2013;27:150-7.
356. Walford GA, Ma Y, Christophi CA, et al. and **Diabetes Prevention Program Research Group**. Circulating natriuretic peptide concentrations reflect changes in insulin sensitivity over time in the Diabetes Prevention Program. *Diabetologia* 2014;57:935-9. PMID: 24554005.
357. Perreault L, Temprosa M, Mather KJ, et al and **Diabetes Prevention Program Research Group**. Regression from prediabetes to normal glucose regulation is associated with reduction in cardiovascular risk: results from the Diabetes Prevention Program outcomes study. *Diabetes Care* 2014;37:2622-31. PMID: 24969574.
358. Delahanty LM, Pan Q, Jablonski KA et al. and **Diabetes Prevention Program Research Group**. Effects of weight loss, weight cycling and weight loss maintenance on diabetes incidence and change in cardiometabolic traits in Diabetes Prevention Program. *Diabetes Care* 2014;37:2738-45. PMID: 25024396.
359. **Diabetes Prevention Program Research Group**. Factors affecting the decline in incidence of diabetes in the Diabetes Prevention Program Outcomes Study. *Diabetes* 2015;64:989-98. PMID 25277389.
360. **Diabetes Prevention Program Research Group**. HbA1c as a predictor of diabetes and as an outcome in the Diabetes Prevention Program: randomized clinical trial. *Diabetes Care* 2015;38:51-8. PMID: 25336746.
361. Aroda VR, Christophi CR, Edelstein SL, et al. and **Diabetes Prevention Program Research Group**. The effect of lifestyle intervention and metformin on preventing or delaying diabetes among women with and without gestational diabetes. *J Clin Endocrinol Metab* 2015;100:1643-53. PMID: 25706240.
362. Rockette-Wagner B, Edelstein S, Venitti EM, et al. and **Diabetes Prevention Program Research Group**. The impact of lifestyle intervention on sedentary time in individuals at high risk of diabetes. *Diabetologia* 2015;58:1198-1202. PMID. 25851102.
363. deGroot M, Marrero D, Mele L, et al.; **Diabetes Prevention Program Research Group**. Depressive symptoms, antidepressant medication use and inflammatory markers in the Diabetes Prevention Program. *Psychosom Med* 2018;80: 167-173. PMID: 29016549.

364. Luchsinger JA, Ma Y, Christophi CA, et al.; **Diabetes Prevention Program Research Group**. Metformin, lifestyle intervention and cognition in the Diabetes Prevention Program Outcomes Study. *Diabetes Care* 2017; 40: 958-65. PMID: 28500216.
365. Herman WH, Pan Q, Edelstein SL, et al; **Diabetes Prevention Program Research Group**. Impact of lifestyle and metformin interventions on the risk to progression and regression to normal glucose regulation in overweight or obese people with impaired glucose regulation. *Diabetes Care* 2017; 40: 1668-77. PMID: 29021207.
366. Kim C, Aroda VR, Goldberg RB, et al; **Diabetes Prevention Program Outcomes Study Group**. Androgens, irregular menses, and the risk of diabetes and coronary artery calcification in the Diabetes Prevention Program. *J Clin Endocrinol Metab.* 2018; 103: 486-96. PMID: 29220533.
367. Chen ZZ, Liu J, Morningstar J, Heckman-Stoddard BM, Lee CG, Dagogo-Jack S, et al.; **Diabetes Prevention Program Research Group**. Metabolite profiles of incident diabetes and heterogeneity of treatment effects in the Diabetes Prevention Program. *Diabetes* 2019; 68: 2337-2349. PMID: 31569249.
368. Perreault L, Pan Q, Schroeder EB, Kalyani RR, Bray GA, Dagogo-Jack S, White NH, Goldberg RB, Kahn SE, Knowler WC, Mathioudakis N, Dabelea D; **Diabetes Prevention Program Research Group**. Regression from prediabetes to normal glucose regulation and prevalence of microvascular disease in the Diabetes Prevention Program Outcomes Study. *Diabetes Care* 2019; 42: 1809-15. PMID: 31320455.
369. Gupta DK, Walford GA, Ma Y, Jarolim P, Wang TJ; **DPP Research Group**. Racial/ethnic differences in circulating natriuretic peptide levels: the Diabetes Prevention Program. *Plos One* 2020; 15:e0229280. PMID: 32084251.
370. Walker EA, Gonzalez JS, Tripputi MT, Dagogo-Jack S, Matulik MJ, et al.; **DPP Research Group**. Long-term metformin adherence in the Diabetes Prevention Program Outcome Study. *BMJ Open Diabetes Res Care* 2020; 8:e001537. PMID: 33023898.
371. Merino J, Jablonski KA, Mercader JM, Kahn SE, Chen L, et al.; **Diabetes Prevention Program Research Group**. Interaction between type 2 diabetes prevention strategies and genetic determinants of coronary artery disease on cardiometabolic risk factors. *Diabetes* 2020; 69:112-20. PMID: 31636172.
372. Aroda VR, Christophi CA, Edelstein SL, Perreault L, Kim, Golden SH, Horton E, Mather KJ; **DPP Research Group**. Circulating *sex hormone binding globulin levels are modified with intensive lifestyle intervention, but their changes did not independently predict diabetes in the Diabetes Prevention Program*. *BMJ Open Diab Res Care* 2020; 8:e001841. PMID: 33328161.
373. Schwartz AV, Pan Q, Aroda VR, Crandall JP, et al.; **Diabetes Prevention Program Research Group**. Long-term effects of lifestyle and metformin interventions in DPP on bone density. *Osteoporosis Int* 2021. Online ahead of print. PMID: 34086101.

**Epidemiology of Diabetes Interventions and Complications (EDIC) Study (selected from >250 papers- <https://edic.bsc.gwu.edu/web/edic/publications>).**  
(D.M. Nathan- Study Chair, Editor for all publications)

374. **EDIC Research Group.** Epidemiology of Diabetes Interventions and Complications (EDIC): Design and implementation of a long-term follow-up of the Diabetes Control and Complications Trial Cohort. *Diabetes Care* 1999; 22:99-111.
375. **EDIC Research Group.** Effect of intensive diabetes treatment on carotid artery wall thickness in the Epidemiology of Diabetes Interventions and Complications. *Diabetes* 1999; 48:383-90.
376. **EDIC Research Group.** Beneficial effect of intensive therapy of diabetes during Adolescence: Outcomes after the conclusion of the Diabetes Control and Complications Trial (DCCT). *Journal of Pediatrics* 2001; 139:804-812.
377. Virella G, Atchley D, Koskinen S, Zheng D, Lopes-Virella MF, and the **DCCT/EDIC Research Group.** Proatherogenic and proinflammatory properties of immune complexes prepared with purified human ox-LDL antibodies and human ox-LDL. *Clin Immunol* 2002;105:81-92.
378. Virella G, Thorpe SR, Alderson NL, Stephan EM, Atchley D, Wagner F, Lopes-Virella MF and the **DCCT/EDIC Research Group.** *J of Lipid Res* 2003; 44:487-93.
379. Jenkins AJ, Lyons TJ, Otvos J, Zheng D, Lackland DT, McGee D, Garvey WT, Klein R and the **DCCT/EDIC Research Group.** NMR analysis of lipoprotein subclasses in the EDIC cohort: associations with gender and glycemia. *Diabetes Care* 2003; 26:810-818.
380. Klein RL, Hunter SJ, Jenkins AJ, Zheng D, Semler AJ, Clore J, Garvey WT and the **DCCT/EDIC Research Group.** Fibrinogen as a marker for nephropathy and peripheral vascular disease in type 1 diabetes: studies of plasma fibrinogen and fibrinogen gene polymorphism in the DCCT/EDIC cohort, *Diabetes Care* 2003; 26: 1439-48.
381. **DCCT/EDIC Research Group.** Glycated hemoglobin measurements over nearly two decades: sustaining comparable values throughout the Diabetes Control and Complications Trial and the Epidemiology of Diabetes Interventions and Complications Study. *Clin Chem* 2005;51: 753-758.
382. Boright A, Patterson A, Mirea L, Bull S, Scherer S, Zinman and the **DCCT/EDIC Research Group.** Genetic variation at the ACE gene is associated with persistent microalbuminuria and severe nephropathy in type 1 diabetes. *Diabetes* 2005; 54: 1238-1244.
383. **DCCT/EDIC Research Group.** Neuropathy among the Diabetes Control and Complications Trial cohort eight years after trial completion. *Diabetes Care* 2006; 29:340-4.
384. Lyons TJ, Jenkins AJ, Zheng D, Klein RL, Otvos JD, Yu Y, Lackland DT, McGee S, McHenry MB, Lopes-Virella M, Garvey WT, and the **DCCT/EDIC Research Group.** Nuclear magnetic resonance-determined lipoprotein subclass profile in the DCCT/EDIC cohort: associations with carotid intima-media thickness. *Diabet Med* 2006;23:955-966.

385. Sibley SD, deBoer IH, Steffes MW, Brunzell JD and the **DCCT/EDIC Research Group**. Intra-abdominal fat and elevated urine albumin excretion in men with type 1 diabetes mellitus. *Diabetes Care* 2007;30:1898-1900.
386. **DCCT/EDIC Research Group**. The effect of intensive diabetes treatment on resting heart rate in type 1 diabetes: the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study. *Diabetes Care* 2007;30:2107-12.
387. Al-Kateb H, Mirea L, Xie X, Sun L, Liu M, Chen H, Bull SB, Boright AP, Paterson AD for the **DCCT/EDIC Research Group**. Multiple variants in vascular endothelial growth factor (VEGFA) are risk factors for time to severe nephropathy in type 1 diabetes. *Diabetes* 2007; 56:2161-68.
388. **DCCT/EDIC Research Group**. Subclinical neuropathy among Diabetes Control and Complications Trial participants without diagnosable neuropathy at trial completion. Possible predictors of incident neuropathy? *Diabetes Care* 2007;30:2613-18.
389. **DCCT/EDIC Research Group**. Intensive treatment of diabetes is associated with a reduced rate of peripheral arterial calcification in Diabetes Control and Complications Trial. *Diabetes Care* 2007;30:2646-48.
390. **Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study Research Group**, Jacobson AM, Musen G, Ryan CM, Silvers N, Cleary P, Waberski B, Burwood A, Weinger K, Bayless M, Dahms W, Harth J. Long-term effect of diabetes and its treatment on cognitive function. *N Engl J Med* 2007; 356:1842-52.
391. Al-Kateb H, Boright AP, Mirea L, Xie X, et al. and the **DCCT/EDIC Research Group**. Multiple SOD1/SFRS15 variants are associated with the development and progression of diabetic nephropathy. *Diabetes* 2008;57: 218-28.
392. deBoer IH, Kestenbaum B, Rue Ts, et al. for the **DCCT/EDIC Study Research Group**. Insulin therapy, hyperglycemia, and hypertension in type 1 diabetes mellitus. *Arch Int Med* 2008;168:1867-73.
393. **DCCT/EDIC Research Group**. Effect of glycemic exposure on the risk of microvascular complications in the Diabetes Control and Complications Trial. *Diabetes* 2008; 57:995-2001.
394. **DCCT/EDIC Research Group**. The impact of diabetes and its treatment on cognitive function among adolescents who participated in the DCCT. *Diabetes Care* 2008; 31:1933-8.
395. Penson DF, Wessells H, Cleary P, Rutledge BN and the **DCCT/EDIC Research Group**. Sexual dysfunction and symptom impact in men with long-standing type 1 diabetes in the DCCT/EDIC cohort. *J Sex Med* 2009; 6:1969-78.
396. Sarma AV, Kanaya , Nyberg LM, et al for the **DCCT/EDIC Research Group**. Risk factors for urinary incontinence among women with type 1 diabetes: findings from the

- Epidemiology of Diabetes Interventions and Complications Study. *Urology* 2009;73: 1203-09.
397. Pop-Busui R, Low PA, Waberski B, et al. for the **DCCT/EDIC Research Group**. Effects of prior intensive insulin therapy on cardiac autonomic nervous system function in type 1 diabetes mellitus. *Circulation* 2009; 119:2886-93.
  398. Pezzolesi MG, et al., the **DCCT/EDIC Research Group**. Genome-wide association scan for diabetic nephropathy susceptibility genes in type 1 diabetes. *Diabetes* 2009;58: 1403-10.
  399. Grant SF, Qu HQ, Bradfield L, et al. **DCCT/EDIC Research Group**. Followup analysis of genome-wide association data identifies novel loci for type 1 diabetes. *Diabetes* 2009;58: 290-5.
  400. **DCCT/EDIC Research Group**. Urinary tract infections in women with type 1 diabetes mellitus: survey of female participants in the Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) study cohort. *J Urology* 2009;181: 1129-35.
  401. **DCCT/EDIC Research Group**. Urinary incontinence among women with type 1 diabetes: how common is it? *J Urology* 2009;181: 1224-30.
  402. **DCCT/EDIC Research Group**. Effect of intensive glycemic control and diabetic complications on lower urinary tract symptoms (LUTS) in men with type 1 diabetes: Diabetes Control and Complications Trial/ Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) study. *Diabetes Care* 2009;32: 664-70.
  403. **DCCT/EDIC Research Group**. Sexual dysfunction in women with type 1 diabetes: Long-term findings from the DCCT/EDIC study cohort. *Diabetes Care* 2009;32:780-85.
  404. **DCCT/EDIC Research Group**. The role of PGC1 alpha Gly482Ser polymorphism in weight gain due to intensive diabetes therapy. *PPAR Research* 2009, in press.
  405. Paterson AD, Lopes-Virella MF, Waggott D, et al. and the **DCCT/EDIC Research Group**. Genome-wide association identifies the ABO blood group as a major locus associated with serum levels of soluble E-selectin. *Athero Thromb Vasc Biol.* 2009, in press.
  406. Albers JW, Herman WH, Pop-Busui R, Feldman EL, Martin CL, Cleary PA, Waberski BH, Lachin JM, **DCCT/EDIC Research Group**. Effect of prior intensive insulin treatment during the Diabetes Control and Complications Trial (DCCT) on peripheral neuropathy in type 1 diabetes during the Epidemiology of Diabetes Interventions and Complications (EDIC) study. *Diabetes Care* 2010;33:1090-6.
  407. Jacobson AM, Paterson AD, Ryan CM, Cleary PA, Waberski BH, Weinger K, Musen G, Dahms W, Bayless M, Silvers N, Harth J, Boright AP, **DCCT/EDIC Research Group**. The associations of apolipoprotein E and angiotensin-converting enzyme polymorphisms and cognitive function in type 1 diabetes based on an 18-year follow-up of the DCCT cohort. *Diabet Med* 2010;27:15-22.
  408. Jacobson AM, Ryan CM, Cleary PA, Waberski BH, Weinger K, Musen G, Dahms W; **Diabetes Control and Complications Trial/EDIC Research Group**. Biomedical risk

- factors for decreased cognitive functioning in type 1 diabetes: an 18 year follow-up of the Diabetes Control and Complications Trial (DCCT) cohort. *Diabetologia*. 2011;54:245-55.
409. **DCCT/EDIC Research Group**. Intensive diabetes therapy and glomerular filtration rate in type 1 diabetes. *N Engl J Med* 2011;365:2366-76.
  410. deBoer IH, Afkarian M, Rue TC, et al. and the **DCCT/EDIC Research Group**. Renal outcomes in patients with type 1 diabetes and macroalbuminuria. *J Am Soc Nephrol* 2014;25:2342-50. PMID: 24925722.
  411. **DCCT/EDIC Research Group**. Effect of intensive diabetes treatment on albuminuria in type 1 diabetes: long-term follow-up of the Diabetes Control and Complications Trial and Epidemiology of Diabetes Interventions and Complications study. *Lancet Diabetes Endocrinol* 2014; 2:293-800. PMID: 25043685.
  412. Pop-Busui R, Hotaling J, Braffett BH, et al. and the **DCCT/EDIC Research Group**. Cardiovascular autonomic neuropathy. Erectile dysfunction and lower urinary tract symptoms in men with type 1 diabetes: Findings from the DCCT/EDIC. *J Urol* 2015;193:2045-51. PMIS: 25584994.
  413. Hunt KJ, Baker NL, Cleary PA, et al. and the **DCCT/EDIC Research Group**. Longitudinal association between endothelial dysfunction, inflammation and clotting biomarkers with subclinical atherosclerosis in type 1 diabetes: an evaluation of the DCCT/EDIC cohort. *Diabetes Care* 2015; epub. PMID: 25852210.
  414. **DCCT/EDIC Research Group**, Lachin JM, White NH, Hainsworth DP, Sun W, Cleary PA, **Nathan DM**. Effect of intensive diabetes therapy on the progression of diabetic retinopathy in patients with type 1 diabetes: 18 years of follow-up in the DCCT/EDIC. *Diabetes* 2015;64:631-42. PMID: 25204977.
  415. Eny KM, Orchard TJ, Miller RG, et al and **DCCT/EDIC Research Group**. Caffeine consumption contributes to skin intrinsic fluorescence in type 1 diabetes. *Diabetes Technol Ther* 2015; 17:726-34.
  416. Kim C, Pop-Busui R, Braffett B, et al. and **DCCT/EDIC Research Group**. Testosterone concentrations and cardiovascular autonomic in men with type 1 diabetes in the Epidemiology of Diabetes Interventions and Complications Study (EDIC). *J Sex Med* 2015; 12:2153-9.
  417. Lenherr SM, Clemens JQ, Braffett BH, et al. and **DCCT/EDIC Research Group**. Glycemic control and urinary tract infections in women with type 1 diabetes: results from the DCCT/EDIC. *J Urol* 2016; 16. [epub ahead of print] PMID:26628417.
  418. Chen Z, Miao F, Patterson AD, et al and **DCCT/EDIC Research Group**. Epigenomic profiling reveals an association between persistence of DNA methylation and metabolic memory in the DCCT/EDIC type 1 diabetes cohort. *Proc Natl Acad Sci* 2016;113 [epub ahead of print]. PMID 27162351.
  419. **DCCT/EDIC Research Group**. Mortality in type 1 diabetes in the DCCT/EDIC versus the general population. *Diabetes Care* 2016;39: 1378-83. PMID: 27411699.

420. **DCCT/EDIC Research Group.** Coprogression of cardiovascular risk factors in type 1 diabetes during 30 years follow-up in DCCT/EDIC study. *Diabetes Care* 2016;39: 1621-30. PMID: 27436274.
421. deBoer IH, Gao X, Cleary PA, et al.; **DCCT/EDIC Research Group.** Albuminuria changes and cardiovascular and renal outcomes in type 1 diabetes: the DCCT/EDIC Study. *Clin J Am Soc Nephrol* 2016;11: 1969-77. PMID: 27797889.
422. Pop-Busui R, Braffett BH, Zinman B, et al.; **DCCT/EDIC Research Group.** Cardiovascular autonomic neuropathy and cardiovascular outcomes in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study. *Diabetes Care* 2017; 40: 94-100. PMID: 27803120.
423. Gubitosi-Klug R, Braffett BH, White N, et al.; **DCCT/EDIC Research Group.** Risk of severe hypoglycemia in type 1 diabetes over 30 years of follow-up in the DCCT/EDIC Study. *Diabetes Care* 2017; 40:1010-16. PMID: 28550194.
424. Purnell JQ, Braffett BH, Zinman B, et al.; **DCCT/EDIC Research Group.** Impact of excessive weight gain on cardiovascular outcomes in type 1 diabetes: Results from the DCCT/EDIC Study. *Diabetes Care* 2017;40: 1756-62. PMID: 29138273.
425. Wessells H, Braffett BH, Holt SK, et al and **DCCT/EDIC Research Group.** Burden of urological complications in men and women with long-standing type 1 diabetes in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study Cohort. *Diabetes Care* 2018;41:2170-7. PMID: 30104298.
426. Roshandel D, Chen Z, Canty AJ, Bull SB, Natarajan R, Paterson AD; **DCCT/EDIC Research Group.** DNA methylation age calculators reveal association with diabetic neuropathy in type 1 diabetes. *Clin Epigenetics.* 2020;12:52. PMID: 32248841.
427. Chen Z, Miao F, Braffett BH, Lachin JM, et al.; **DCCT/EDIC Research Group.** DNA methylation mediates development of HbA1c-associated complications in type 1 diabetes. *Nat Metab.* 2020;2: 744-62. PMID: 32694834.
428. Bebu I, Braffett BH, Schade D, et al.; **DCCT/EDIC Research Group.** An observational study of the equivalence of age and duration of diabetes to glycemic control relative to the risk of complications in the combined cohorts of the DCCT/EDIC study. *Diabetes Care* 2020; 43:2478-84. PMID: 32788280.
429. Hainsworth DP, Gao X, Bebu I, et al.; **DCCT/EDIC Research Group.** Refractive error and retinopathy outcomes in type 1 diabetes: The DCCT/EDIC Study. *Ophthalmology* 2021; 128: 554-60. PMID: 32941962.
430. Gubitosi-Klug RA, Braffett BH, Hitt S, et al.; **DCCT/EDIC Research Group.** Residual  $\beta$  cell function in long-term type 1 diabetes associates with reduced incidence of hypoglycemia. *J Clin Inv* 2021;131:ee143011. PMID: 33529168.
431. Gubitosi-Klug R, Gao X, Pop-Busui T, et al.; **DCCT/EDIC Research Group.** Associations of microvascular complications with the risk of cardiovascular disease in type 1 diabetes. *Diabetes Care* 2021; 44:1499-505. PMID: 33980605.

432. Jacobson AM, Ryan CM, Braffett BH, et al.; **DCCT/EDIC Research Group**. Cognitive performance declines in older adults with type 1 diabetes: results from 32 years of follow-up in the DCCT and EDIC Study. *Lancet Diabetes Endocrinol* 2021;9:436-445. PMID: 34051936.

**Look:AHEAD Study (D.M. Nathan, PI of Boston/Harvard Center selected from more than 180 publications- <https://www.lookaheadtrial/dsp/Bibliography.cfm>)**

433. **Look:AHEAD** (Action for Health in Diabetes): design and methods for a clinical trial of weight loss for the prevention of cardiovascular disease in type 2 diabetes. *Controlled Clinical Trials* 2003;24:610-628.
434. **Look AHEAD Research Group**. Baseline characteristics of the randomized cohort from the Look AHEAD (Action for Health in Diabetes) study. *Diab Vasc Dis Res* 2006;3:202-15.
435. **Look AHEAD Research Group**. Reduction in weight and cardiovascular disease risk factors in individuals with type 2 diabetes. *Diabetes Care* 2007; 30: 1374-1383.
436. **Look AHEAD Research Group**. Impact of weight management program on health-related quality of life in overweight adults with type 2 diabetes. *Arch Int Med* 2009;169:163- 71.
437. Wadden TA, West DS, Neiberg RH, Wing RR, Ryan DH, Johnson KC, Foreyt JP, Hill JO, Trencle DL, Vitolins MZ; **Look AHEAD Research Group**. One-year weight losses in the Look AHEAD study: factors associated with success. *Obesity* 2009;17:713-22.
438. Williamson D, Rejeski J, Lang W, Van Dorsten B, Fabricatore AN, Toledo K; LookAHEAD Research Group. Impact of weight management program on health-related quality of life in overweight adults with type 2 diabetes. *Arch Int Med* 2009;169: 163-71.
439. **Look AHEAD Research Group**. Long-term effects of a lifestyle intervention on weight and cardiovascular risk factors in individuals with type 2 diabetes mellitus: four-year results of the Look AHEAD trial. *Arch Int Med* 2010; 170:1566-75.
440. **Look AHEAD Research Group**. Four-year weight loss in the LookAHEAD study: factors associated with long-term success. *Obesity* 2011;19:1987-98.
441. Smart-Halajko MC, Kelley-Hedgepeth A, Montefusco MC, Cooper JA, Kopin A, McCaffrey JM, Balasubramanyam A, Pownall HJ, **Nathan DM**, Peter I, Talmud PJ, Huggins GS, LookAHEAD Study. ANGPTL4 variants E40K and T266M are associated with lower fasting triglyceride levels in non-hispanic white Americans from the LookAHEAD clinical trial. *BMC Med Genet* 2011;12:89.
442. Rejeski WJ, Ip EH, Bertoni AG, Bray GA, Evans G, Gregg EW, Zhang Q; **Look AHEAD Research Group**. Lifestyle change and mobility in obese adults with type 2 diabetes. *N*

*Engl J Med.* 2012;366:1209-17.

443. Rubin RR, Wadden TA, Bahnson JL, et al. **Nathan DM** and the **Look AHEAD Research Group**. Effect of intensive lifestyle intervention on depression and health-related quality of life in type 2 diabetes: the Look AHEAD Trial. *Diabetes Care* 2014; 37:1544-53. PMID: 24855155.
444. **Look AHEAD Research Group**. Effect of long-term behavioural weight loss intervention on nephropathy in overweight or obese adults with type 2 diabetes: a secondary analysis of the Look AHEAD randomized clinical trial. *Lancet Diabetes Endocrinol* 2014; 2:801-9. PMID: 25127483.
445. McCaffery JM, Papandonatos GD, Faulconbridge LF et al, and the **Look AHEAD Research Group**. Genetic predictors of depressive symptoms in the Look AHEAD Trial. *Psychosom Med* 2015; 77:982-92. PMID:263489030.
446. Belalcazar LM, Lang W, Haffner SM, et al. and **Look AHEAD Research Group**. Improving adiponectin levels in individuals with diabetes and obesity: insights from Look AHEAD. *Diabetes Care* 2015; 38:1544-50. PMID:26972574.
447. Unick JL, Neiberg RH, Hogan PE, et al. and **Look AHEAD Research Group**. Weight change in the first two months of a lifestyle intervention predicts weight changes 8 years later. *Obesity* 2015; 23:1353-6. PMID:26110890.
448. **Look AHEAD Research Group**. Prospective association of GLUL rs10911021 with cardiovascular morbidity and mortality among individuals with type 2 diabetes: the Look AHEAD Study. *Diabetes* 2016; 65:297-302. PMID: 26395743.
449. McCaffery JM, Papandonatos GD, Faulconbridge LF, et al. and the **Look AHEAD Research Group**. Genetic predictors of depressive symptoms in the Look AHEAD Trial. *Psychosom Med* 2015;77:982-92. PMID: 26489030.
450. **Look AHEAD Research Group**. Association of the magnitude of weight loss and changes in physical fitness with long-term cardiovascular disease outcomes in overweight or obese people with type 2 diabetes: a post-hoc analysis of the Look AHEAD randomised clinical trial. *Lancet Diabetes Endocrinol* 2016; 4:913-21
451. Kline CE, Reboussin DM, Foster GD, et al; **Look AHEAD Research Group**. The effect of changes in cardiorespiratory fitness and weight on obstructive sleep apnea severity in overweight adults with type 2 diabetes. *Sleep.* 2016;39: 317-25. PMID: 26446118.
452. Zhang P, Hire D, et al.; **Look AHEAD Research Group**. Impact of intensive lifestyle intervention on preference based quality of life in type 2 diabetes: Results from the Look AHEAD Trial. *Obesity* 2016;24:856-64. PMID: 27028282.
453. **Look AHEAD Research Group**. Severe hypoglycemia in the Look AHEAD Trial. *J Diabetes Complications* 2016;30:935-43. PMID: 27114389.
454. **Look AHEAD Research Group**. Association of the magnitude of weight loss and changes in physical fitness with long-term cardiovascular disease outcomes in overweight or obese

people with type 2 diabetes: a post-hoc analysis of the Look AHEAD randomized clinical trial. *Lancet Diabetes Endocrinol* 2016;4: 913-21. PMID: 27595918.

455. **Look AHEAD Research Group.** Effects of a long-term lifestyle modification programme on peripheral neuropathy in overweight or obese adults with type 2 diabetes: the Look AHEAD Study. *Diabetologia* 2017;60: 980-88. PMID: 28349174.
456. Gregg EW, Bardenheier B, Chen H, et al.; **Look AHEAD Research Group.** Impact of lifestyle intervention on disability-free life expectancy: the Look AHEAD Study. *Diabetes Care* 2018; epub March 2018. PMID: 29545462.
457. **Look AHEAD Research Group,** Lewis CE, Bantle JP, Bertoni AG, Blackburn G, Brancata FL, Bray GA, Cheskin LJ, Curtis JM, Egan C, Evans M, Foreyt JP, Ghazarian S, Barone Gibbs B, Glasser SP, Gregg EW, Hazuda HP, Hesson L, Hill JO, Horton ES, Hubbard VS, Jakicic JM, Jeffery EW, Johnson KC, Kahn SE, Kitabchi AE, Kitzman D, Knowler WC, Lipkin E, Michaels S, Montez MG, **Nathan DM,** et al. History of cardiovascular disease, intensive lifestyle intervention and cardiovascular outcomes in the Look AHEAD Trial. *Obesity* 2020; 28:247-58. PMID: 31898874.
458. **Look AHEAD Research Group,** Yeh HC, Bantle JP, Cassidy-Begay M, Blackburn G, Bray GA, Byers T, Clark JM, Coday M, Egan C, Espeland MA, Foreyt JP, Garcia K, Goldman V, Gregg EW, Hazuda HP, Hesson L, Hill JO, Horton ES, Jakicic JM, Jeffery RW, Johnson KC, Kahn SE, Knowler WC, Korytkowski M, Kure A, Lewis CE, Mantzoros C, Meacham M, Montez MG, **Nathan DM,** Pajewski N, Patricio J, Peters A, Xavier Pi-Sunyer F, Pownall H, Ryan DH, Safford M, Sedjo RL, Steinburg H, Vitolins M, Wadden TA, Wagenknecht LE, Wing RR, Wolff AC, Wyatt H, Yanovski SZ. Intensive weight loss intervention and cancer risk in adults with type 2 diabetes: analysis of the Look AHEAD randomized clinical trial. *Obesity* 2020; 28:1678-86. PMID: 32841523.

**TODAY Study (D.M. Nathan, PI of Boston/Harvard Center selected from more than 60 publications)**

459. **TODAY Study Group.** Treatment Options for type 2 diabetes in adolescents and youth: a study of the comparative efficacy of metformin alone or in combination with rosiglitazone or lifestyle intervention in adolescents with type 2 diabetes. *Ped Diabetes* 2007; 8: 74-87.
460. Copeland KC, Zeitler P, Geffner M, et al. and the **TODAY Study Group.** Characteristics of the adolescents and youth with recent-onset type 2 diabetes: the TODAY cohort at baseline. *J Clin Endocrinol Metab* 2011;96:159-67.
461. Bacha F, Pyle L, Nadeau K, et al and the **TODAY Study Group.** Determinants of glycemic control in youth with type 2 diabetes at randomization in the TODAY study. *Pediatr Diabetes* 2013;13:376-83. PMID: 22332798.
462. Walders-Abramson N, Venditti EM, Levers-Landis CE, et al. and the **TODAY Study Group.** Relationships among stressful life events and physiological markers, treatment adherence and psychosocial functioning among youth with type 2 diabetes. *J Pediatr* 2014;165:504-8. PMID: 24948348.

463. Kelsey MM, Geffner ME, Guandalini C, et al. and the **TODAY Study Group**. Presentation and effectiveness of early treatment of type 2 diabetes in youth: lessons from the TODAY Study. *Pediatr Diabetes* 2015;epub. PMID: 25690268.
464. Weinstock RS, Drews KL, Caprio S, et al and the **TODAY Study Group**. Metabolic Syndrome is common and persistent in youth-onset type 2 diabetes: results from the TODAY clinical trial. *Obesity*. 2015 epub. PMID 26047470.
465. Klingensmith GJ, Pyle L, Nadeau, et al. and **TODAY Study Group**. Pregnancy outcomes in youth with type 2 diabetes. *Diabetes Care* 2016;39:122-9. PMID: 26628417.
466. Bjornstad P, Nehus E, El Ghormil L, et al.; **TODAY Study Group**. Insulin sensitivity and diabetic kidney disease in children and adolescents with type 2 diabetes: an observational analysis of data from the TODAY clinical trial. *Am J Kidney Dis* 2018;71: 65-74. PMID: 29157731.
467. Gidding SS, et al. and **TODAY Study Group**. Cardiac biomarkers in youth with type 2 diabetes: results from the TODAY Study. *J Pediatr* 2018 Jan; [Epub ahead of print]. PMID: 29246363
468. Arslanian S, El Ghormili L, Young KJ, Bacha F, et al. and **TODAY Study Group**. The shape of the glucose response curve during an oral glucose tolerance test: forerunner of heightened glycemic failure rates and accelerated decline in B-cell function in TODAY. *Diabetes Care* 2019;42: 164-72. PMID: 30344329.
469. Bacha F, El Ghormii L, Arslanian S, Zeitler P, Laffel LM, Levitt-Katz LE, et al; **TODAY Study Group**. Predictors of response to insulin therapy in youth with poorly-controlled type 2 diabetes in the TODAY Trial. *Pediatr Diabetes* 2019;20: 871-9. PMID: 31418516.
470. **TODAY Study Group**. Longitudinal changes in vasculr stiffness and heart rate variability among young adults with youth-onset type 2 diabetes: results from the follow-up observational treatment options for type 2 diahetes in adolescents and youth (TODAY) study. *Acta Diabetol* 2021. Online publication ahead of print.
471. **TODAY Study Group**. Health care coverage and glycemic control in young adults with youth-onset type 2 diabetes: results from the TODAY2 Study. *Diabetes Care* 2020; 43:2469-77.

**Glycemic Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE) (D.M. Nathan, Study Chair, Principal Investigator). Selected from 16 publications.**

472. Wexler DJ, Krause-Steinrauf H, Crandall JP, Florez HJ, Hosx SH, Kuhn A, Sood A, Underkofler C, Aroda VR; **GRADE Research Group**. Baseline characteristics of randomized participants in the Glycemic Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE). *Diabetes Care* 2019 Aug 7, epub ahead of print. PMID: 31391203.

473. Larkin ME, **Nathan DM**, Bebu I, et al; GRADE Research Group. Rationale and design for a GRADE substudy of continuous glucose monitoring. *Diabetes Technol Ther* 2019 Sept 4 [Epub ahead of print] PMID: 31393176.
474. Rasouli N, Younes N, Utzschneider KM, Inzucchi SE, Balasubramanyam A, Cherrington AL, Ismail-Beigi F, Cohen RM, Olson DE, DeFronzo RA, Herman WH, Lachin JM, Kahn SE; **GRADE Research Group**. Association of baseline characteristics with insulin sensitivity and B-cell function in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness (GRADE) study cohort. *Diabetes Care* 2020; 44:340-9. PMID: 33334808.
475. Sivitz WI, Phillips LS, Wexler DJ, Fortmann SP, Camp AW, Tiktin M, Perez M, Craig J, Hollander PA, Cherrington A, Aroda VR, Tan MH, Krakoff J, Rasouli N, Butera NM, Younes N; **GRADE Research Group**. Optimization of metformin in the GRADE cohort: effect on glycemia and body weight. *Diabetes Care* 2020;43: 940-7. PMID: 32139384.
476. Mather KJ, Bebu I, Baker C, et al.; **GRADE Research Group**. Prevalence of microvascular and macrovascular disease in the Glycemia Reduction Approaches in Diabetes- A Comparative Effectiveness (GRADE) study cohort. *Diab Res Clin Pract* 2020 Jul; 165. PMID: 32450102.
477. Utzschneider KM, Younes N, Rasouli N, et al.; **GRADE Research Group**. Shape of the OGTT glucose response curve: relationship with beta-cell function and difference by sex, race and BMI in adults with early type 2 diabetes treated with metformin. *BMJ Open Diab Res Care* 2021 Sep; 9(1) e002264. PMID: 34531242.
478. Luchsinger JA, Younes N, Barzilay J, et al.; **GRADE Research Group**. Association of glycemia, lipids, and blood pressure with cognitive performance in people with type 2 diabetes in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE). *Diabetes Care* 2021; 44:2286-92. PMID: 34285097.

#### **MAGIC and other Genetic Consortia (from more than 30 publications)**

479. **MAGIC Investigators**. Genetic variation in GIPR influences the glucose and insulin responses to an oral glucose challenge. *Nat Genet* 2010; 42:142-8. PMID: 20081857
480. **MAGIC Investigators**. New genetic loci implicated in fasting glucose homeostasis and their impact on type 2 diabetes risk. *Nat Genet* 2010;42: 105-16.
481. **MAGIC Investigators**. Diverse physiologic characterization reveals diverse mechanisms for novel genetic loci regulating glucose and insulin metabolism in humans. *Diabetes* 2010; Epub ahead of print. PMID:20185807
482. **MAGIC Investigators**. Common variants at ten genetic loci influence hemoglobin A1c levels via glycemic and non-glycemic pathways. *Diabetes* 2010; 59:3229-39.
483. **MAGIC Investigators**. The Lin28/let-7 axis regulates glucose metabolism. *Cell* 2011; 147: 81-94.

484. Fox CS, et al. and **MAGIC Consortium**. Genome-wide association for abdominal subcutaneous and visceral adipose reveals a novel locus for visceral fat in women. *PLoS Genet* 2012; Epub May 8; 8(5):e1002695. PMID: 22589738.
485. **Diabetes Genetics Replication and Meta-analysis Consortium**; Myocardial Infarction Genetics Consortium, Kathiresan S, Wijmenga C, Gregersen PK, Alfredsson L, Siminovitch KA, Worthington J, de Bakker PI, Raychaudhuri S, Plenge RM. Bayesian inference analyses of the polygenic architecture of rheumatoid arthritis. *Nat Genet.* 2012; 44:483-9. PMID: 22446960
486. **MAGIC Investigators**. A genome-wide association search for type 2 diabetes genes in African Americans. *PLoS One.* 2012;7(1):e29202. Epub 2012 Jan 4. PMID: 22238593

### ***Books and Book Chapters:***

1. Perlmutter LC, **Nathan DM**, Hakami MK. Effects of diabetic treatment and gender on sensory functions in the elderly. In: Handbook of Nutrition in the Aged. Watson R, Ed. CRC Press: Boca Raton, 1985.
2. **Nathan DM**. Special subcutaneous insulin infusion regimens in brittle diabetes. In: Brittle Diabetes. Pickup J, Ed. Blackwell Scientific Publications Ltd: Oxford, 1985, pp. 232-240.
3. Perlmutter LC, **Nathan DM**, Hakami MK, Chauncey HH. Effect of non-insulin-dependent diabetes mellitus on gustation and olfaction. In: Interaction of the Chemical Senses with Nutrition. Kare and Brand, Eds. Academic Press: Orlando, FL, 1986, pp. 128-142.
4. Singer DE, Samet JH, Coley CM, **Nathan DM**. Screening for diabetes mellitus. In: Preventing Disease: Beyond the Rhetoric. Goldbloom R, Lawrence RS, Eds. Springer-Verlag: New York, 1989.
5. Singer DE, Samet JH, Coley CM, **Nathan DM**. Screening for diabetes mellitus. In: U.S. Preventative Services Task Force Report: Guide to Clinical Preventative Services. 1989, pp. 64-70.
6. Perlmutter LC, Goldfinger SH, Shore AR, **Nathan DM**. In: Neuropsychological and Behavioral Aspects of Diabetes. Holmes C, Ed. Springer-Verlag: New York, 1990.
7. Singer DE, Samet JH, Coley CM, **Nathan DM**. Screening for diabetes mellitus. In: A Yearbook Guide to Clinical Medicine. Stein JH, Ed. Yearbook Publishers: Chicago, 1990.
8. **Nathan DM**. To screen or not to screen. In: Frontiers of Diabetes Research: Current Trends in Non-Insulin-Dependent Diabetes Mellitus. Alberti KGGM, Mazze R, Eds. Elsevier Science Publishers: Amsterdam, 1990.
9. **Nathan DM**. Insulin treatment in the elderly diabetic patient. In: Clinics in Geriatric Medicine. Froom J, Ed. W.B. Saunders: Philadelphia, 1990.
10. Singer DE, Coley CM, Samet JH, **Nathan DM**. Tests of glycemia in diabetes mellitus: their use in establishing a diagnosis and in treatment. In: Common Diagnostic Tests: Use and

Interpretation, 2<sup>nd</sup> Edition. Sox HC, Ed. American College of Physicians: Philadelphia, 1990; pp. 121-147.

11. Singer DE, Samet JH, Coley CM, **Nathan DM**. Screening for diabetes mellitus. In: Common Screening Tests. Eddy DM, Ed. American College of Physicians: Philadelphia, 1991; pp. 154-178.
12. **Nathan DM**. Diabetes Mellitus in adults. In: Conn's Current Therapy. Rakel R, Ed. W.B. Saunders: Philadelphia, 1991; pp. 495-502.
13. **Nathan DM**. Monitoring diabetes mellitus. In: Therapy for Diabetes Mellitus and Related Disorders. American Diabetes Association: Alexandria VA, 1991. 2<sup>nd</sup> Edition, 1994; pp. 87-92.
14. **Nathan DM**. The relationship between metabolic control and long-term complications. In: Joslin's Diabetes Mellitus, 13<sup>th</sup> Edition. Weir GC, Kahn CR, Eds. Lea & Febiger: Philadelphia, 1992; pp.620-30.
15. **Nathan DM**. Diabetes mellitus. In: Scientific American Medicine. Federman DD, Rubenstein E, Eds. Scientific American: New York, 1992.
16. **Nathan DM**. Hypoglycemia. In: Scientific American Medicine. Federman DD, Rubenstein E, Eds. Scientific American: New York, 1992, 1996.
17. **Nathan DM**. Detection and treatment of complications. In: Medical Management of Non-Insulin-Dependent Diabetes, 3<sup>rd</sup> Edition. Raskin P, Ed. American Diabetes Association: Alexandria VA, 1994; pp. 63-86.
18. **Nathan DM**. Insulin management of NIDDM. In: Ellenberg and Rifkin's Diabetes Mellitus, 5<sup>th</sup> Edition. Porte D, Sherwin R, Eds. Appleton & Lange: Norwalk CT, 1995.
19. **Nathan DM**. Diabetes Mellitus. In: Yearbook of Endocrinology 1994. Bagdade JD, Ed. Mosby-Yearbook, Inc.: Chicago IL, 1994; pp. 313-350.
20. **Nathan DM**. Diabetes Mellitus. In: Yearbook of Endocrinology 1995. Bagdade JD, Ed. Mosby-Yearbook, Inc.: Chicago IL, 1995; pp. 297-332.
21. **Nathan DM**. Diabetes Mellitus. In: Yearbook of Endocrinology 1996. Bagdade JD, Ed. Mosby-Yearbook, Inc.: Chicago IL, 1996; 315-357.
22. **Nathan DM**. The treatment of diabetes to prevent and delay long-term complications: The Diabetes Control and Complications Trial. In: Diabetes Mellitus: A Fundamental and Clinical Text. LeRoith D, Olefsky J, Taylor S, Eds. J.P. Lippincott-Raven: Philadelphia, 1996; 373-78. Wilkins, Phil PA, 2004, pp 1077-1084.
23. **Nathan DM** with Lauerma JF. Diabetes. Time Books- Random House, New York, 1997.
24. **Nathan DM**. Monitoring diabetes mellitus. In: Therapy for Diabetes Mellitus and Related Disorders. American Diabetes Association: Alexandria VA, 1991; 3<sup>rd</sup> Edition, 1998; pp.109-117.

25. **Nathan DM.** Diabetes Mellitus. In: Yearbook of Endocrinology 1997. Bagdade JD, Ed. Mosby. Chicago IL, 1997; 289-328.
26. **Nathan DM.** Diabetes Mellitus. In: Yearbook of Endocrinology 1998. Bagdade JD, Ed. Mosby. St. Louis MO, 1998; 293-332.
27. **Nathan DM.** Management and prevention of complications in Type 1 diabetes mellitus. In: Atlas of Clinical Endocrinology, Volume II, Diabetes. Kahn CR, Ed. Current Medicine, Phil PA, 1999; 60-67.
28. **Nathan DM.** A Special Report- Diabetes. Harvard Health Letter, Harvard Medical School Health Publications, Boston, 1999; 1-46.
29. **Nathan DM.** Diabetes Mellitus. In : World Book Encyclopedia 2000. World Book Publishing. Chicago IL, 2000.
30. **Nathan DM** and Cagliero E. Diabetes Mellitus. In: Endocrinology and Metabolism, 4<sup>th</sup> ed. Felig P, Frohman LA, Eds. WB Saunders Co. Phil PA, 2001, pp 827-926.
31. **Nathan DM.** Insulin treatment of Type 2 diabetes mellitus. In: Ellenberg and Rifkins Diabetes Mellitus, 6<sup>th</sup> edition, Porte D, Sherwin R, Eds. McGraw-Hill, NY, 2003; pp 515-522.
32. **Nathan DM.** The relationship between metabolic control and long-term complications. In: Joslin's Diabetes Mellitus, 14<sup>th</sup> Edition. Weir GC, Kahn CR, Eds. Lea & Febiger: Philadelphia, 2004.
33. Saunders C, Frishman R, **Nathan DM.** Diabetes- A Plan for Living. Special Health Report from Harvard Medical School. Harvard Health Publications, 2001.
34. **Nathan DM.** Management and prevention of complications in Type 1 diabetes mellitus. In: Atlas of Clinical Endocrinology, Volume II, Diabetes. 2<sup>nd</sup> ed. Skyler J, ed. Current Medicine, Phil PA, 2002; pp 60-70.
35. **Nathan DM.** Windows of Opportunity. In: Diabetes: A Global Perspective, Bouter PK, ed. Mark Two Communications, The Netherlands, 2003, pp 186-197.
36. **Nathan DM**, Hamman RF, Garfield S, Brenneman A, Fowler SF, Knowler WC. Preventing Type 2 Diabetes: The Diabetes Prevention Program. In: Diabetes mellitus: A Fundamental and Clinical Text, 3<sup>rd</sup> edition. LeRoith D, Olefsky J, Taylor SI, ed. Lippincott Williams & Wilkins, Phil PA, 2004, pp 1077-1084.
37. **Nathan DM.** Insulin Treatment of Type 2 Diabetes Mellitus. In: The Diabetes Mellitus Manual: A Primary Care Companion to Ellenberg and Rifkin's Diabetes Mellitus. 1<sup>st</sup> ed. Inzucchi S, ed. McGraw Hill, NY, NY, 2004, pp 138-149.
38. Diabetes - A Plan for Living. **Nathan DM**, ed. Harvard Health Publications, Boston, MA 2004.
39. Healthy Eating for Type 2 Diabetes. **Nathan DM**, ed. Harvard Health Publications, Boston, MA 2004.

40. **Nathan DM**, Delahanty L. Beat Diabetes. McGraw Hill, NY, NY, 2005.
41. **Nathan DM**. Diabetes control and long-term complications. In: Endocrinology, 5<sup>th</sup> edition. DeGroot LJ, Jameson JL, ed. Elsevier Saunders, Philadelphia, PA, 2005, pp. 1293-1304.
42. Lachin JM, Cleary P, Crofford O, Genuth S, **Nathan DM**, Clark C, Ferris F, Siebert C. Early termination of the Diabetes Control and Complications Trial. In: Data Monitoring in Clinical Trials. DeMets DL, Furberg CD, Friedman LM, ed. Springer, NY, NY, 2006, pp. 93-108.
43. Eisenstadt S, **Nathan DM**. Everywoman's Guide to Diabetes. Harvard University Press, Cambridge, MA, 2006.
44. Genuth SM, Palmer JP, **Nathan DM**: Classification and diagnosis of diabetes. Chapter 1 in *Diabetes in America*, 3rd ed. Cowie CC, Casagrande SS, Menke A, Cissell MA, Eberhardt MS, Meigs JB, Gregg EW, Knowler WC, Barrett-Connor E, Becker DJ, Brancati FL, Boyko EJ, Herman WH, Howard BV, Narayan KMV, Rewers M, Fradkin JE, Eds. Bethesda, MD, National Institutes of Health, NIH Pub No. 17-1468, 2017, p. 1.1–1.39
45. Knowler WC, Crandall JP, Chiasson JL, **Nathan DM**: Prevention of type 2 diabetes. Chapter 38 in *Diabetes in America*, 3rd ed. Cowie CC, Casagrande SS, Menke A, Cissell MA, Eberhardt MS, Meigs JB, Gregg EW, Knowler WC, Barrett-Connor E, Becker DJ, Brancati FL, Boyko EJ, Herman WH, Howard BV, Narayan KMV, Rewers M, Fradkin JE, Eds. Bethesda, MD, National Institutes of Health, NIH Pub No. 17-1468, 2017, p. 38.1–38.21

**Abstracts (more than 400 abstracts)**

1/1/2022

A handwritten signature in black ink that reads "David Nathan". The signature is written in a cursive, flowing style.